UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported) August 2, 2019

 

Accelerate Diagnostics, Inc.

 

(Exact name of registrant as specified in its charter)

 

Delaware

 

(State or other jurisdiction of incorporation)

 

001-31822 84-1072256
(Commission File Number) (IRS Employer Identification No.)

 

3950 South Country Club Road, Suite 470, Tucson, Arizona 85714
(Address of principal executive offices) (Zip Code)

 

(520) 365-3100

 

(Registrant’s telephone number, including area code)

 

Not Applicable

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbol   Name of each exchange on which
registered
Common Stock, $0.001 par value per share   AXDX  

The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

     

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 8, 2019, Accelerate Diagnostics, Inc. (the “Company”) issued a press release announcing its financial results of operations for the quarter ending June 30, 2019. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference in its entirety.

 

In accordance with General Instruction B.2 for Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 8, 2019, the Company announced the appointment of John (Jack) Phillips as Chief Operating Officer of the Company. In accordance with Mr. Phillips’ offer letter (the “Offer Letter”), Mr. Phillips began serving as Chief Operating Officer of the Company on a part-time basis on August 6, 2019 and will serve as Chief Operating Officer of the Company on a full-time basis starting September 1, 2019. Unless terminated earlier in accordance with the terms of the Offer Letter, Mr. Phillips’ employment will continue until September 1, 2021 and will automatically renew for additional one-year periods unless either the Company or Mr. Phillips provides notice prior to the end of the then-current term.

 

Mr. Phillips, age 54, has served as President and Chief Executive Officer of Roche Diagnostics Corporation, a division of Roche Holding AG, a biotech company, since January 2010 and will continue through the end of August 2019. As President and Chief Executive Officer of Roche Diagnostics Corporation, Mr. Phillips was accountable for commercial operations, performance and strategy of approximately 4,200 employees in the United States and Canada. He also served as a member of Roche’s global Diagnostics Leadership Team. Prior to his role as President and Chief Executive Officer of Roche Diagnostics Corporation, Mr. Phillips held senior leadership roles at Ventana Medical Systems, a cancer diagnostic company and a member of the Roche Group, including Senior Vice President of Commercial Operations for North America and Japan from July 1999 to December 2009. Before joining Ventana Medical Systems, Mr. Phillips worked at Bayer Diagnostics and Motorola. Mr. Phillips holds a B.S. in marketing from Northern Kentucky University.

 

Pursuant to the terms of the Offer Letter, Mr. Phillips is entitled to receive, among other things, the following compensation and benefits:

 

· an annual base salary of $495,000;

 

· a signing bonus of $100,000, subject to the conditions set forth in the Offer Letter;

 

     

 

  

· reimbursement of up to $200,000 of expenses incurred in connection with his relocation to the Tucson metropolitan area, subject to the conditions set forth in the Offer Letter;

 

· on August 6, 2019, an initial grant of options to purchase 1,249,917 shares of the Company’s common stock under the Company’s 2012 Omnibus Equity Incentive Plan (the “Plan”) at an exercise price of $17.00 per share, with 40% of such options to vest on the second anniversary of the date of grant and the remaining 60% of such options to vest in 36 equal monthly installments thereafter, subject to such other terms and conditions set forth in the nonqualified stock option agreement entered into between the parties (the “Option Award Agreement”);

 

· beginning January 1, 2020, eligibility to participate in the Company’s annual cash incentive program, with a target incentive bonus of 100% of his base salary and a maximum incentive bonus of 150% of his base salary;

 

· beginning January 1, 2021, eligibility to receive stock options, performance shares and other awards under the Plan; provided that, for the 2021 calendar year, Mr. Phillips will receive an equity award grant equal to 400% of his then base salary and will consist of an award mix of 50% non-qualified stock options and 50% performance shares;

 

· in the event of termination of full-time employment by the Company without Cause (as defined in the Offer Letter) or by Mr. Phillips with Good Reason (as defined in the Offer Letter) prior to a Change of Control (as defined in the Plan), a severance payment equal to the sum of: (i) 12 months of his then base salary and (ii) his average earned under the Company’s annual cash incentive program over the term of his employment, plus a pro-rated amount under the Company’s annual cash incentive program for the year in which termination occurs;

 

· in the event of termination of full-time employment by the Company without Cause or by Mr. Phillips with Good Reason during the 12 month period following a Change of Control, a severance payment equal to the sum of: (i) 18 months of his then base salary and (ii) 18 times the monthly amount that is charged to COBRA qualified beneficiaries for the same medical coverage options elected by Mr. Phillips immediately prior to his last day of employment, plus a pro-rated amount under the Company’s annual cash incentive program for the year in which termination occurs; and

 

· upon a Change of Control, Mr. Phillips’ options and other equity awards shall fully vest and become exercisable.

 

The payments due on termination of full-time employment by the Company without Cause or by Mr. Phillips with Good Reason are subject to the requirement that Mr. Phillips execute (and not revoke) a general release and waiver of any claims in connection with his employment and termination of employment with the Company and its affiliates. Pursuant to the Offer Letter, Mr. Phillips has also agreed to certain undertakings regarding non-solicitation and non-competition.

 

     

 

  

Additionally, the Company has agreed to offer Mr. Phillips the opportunity to purchase (in Mr. Phillips’ sole and absolute discretion) an aggregate of approximately $1,000,000 of shares of the Company’s common stock in an offering (the “Private Placement”) exempt from registration pursuant to Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder. The price of the shares to be sold in the Private Placement will be in accordance with Nasdaq rules relating to the “market value” of the shares, which shall equal the consolidated closing bid price immediately preceding the time the Company enters into the related securities purchase agreement for the sale of the shares.

 

There are no arrangements or understandings between Mr. Phillips and any other person pursuant to which he was appointed to serve as an executive officer of the Company. There are also no family relationships between Mr. Phillips and any director or executive officer of the Company, and Mr. Phillips does not have a direct or indirect material interest in any “related party” transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K other than the Private Placement transaction discussed above.

 

The foregoing description of the Offer Letter and the Option Award Agreement is not complete and is qualified in its entirety by reference to the full text of the Offer Letter and the Option Award Agreement, which are filed herewith as Exhibit 10.1 and Exhibit 10.2, respectively, and incorporated herein by reference in their entirety.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On August 2, 2019, the Board amended and restated the Company’s bylaws (the “Amended and Restated Bylaws”) to, among other things:

 

· incorporate an advance notice provisions relating to certain timing and information requirements for stockholder nominations and proposals brought before a meeting of the stockholders by a stockholder of record;

 

· clarify director nominee eligibility requirements and procedures for nomination;

 

· add a Delaware forum selection provision for adjudication of certain disputes;

 

· update the indemnification provisions to conform to the indemnification provisions in the Company’s charter; and

 

· make certain other technical, procedural, conforming and clarifying changes in order to, among other things, reflect current market practices.

 

The foregoing summary does not constitute a complete summary of the changes included in the Amended and Restated Bylaws and is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws, which is filed herewith as Exhibit 3.1 and incorporated herein by reference in its entirety.

 

     

 

  

Item 8.01 Other Events.

 

On August 8, 2019, the Company issued a press release announcing Mr. Phillips’ hiring, which is filed herewith as Exhibit 99.2 and incorporated herein by reference in its entirety.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit    
Number   Description
     
3.1   Amended and Restated Bylaws
     
10.1   Offer Letter between Accelerate Diagnostics, Inc. and John J. Phillips, dated August 6, 2019
     
10.2   Nonqualified Stock Option Agreement between Accelerate Diagnostics, Inc. and John J. Phillips, dated August 6, 2019
     
99.1   Press Release, dated August 8, 2019 (announcing financial results for the quarter ending June 30, 2019)
     
99.2   Press Release, dated August 8, 2019 (announcing the hiring of John J. Phillips)

 

     

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ACCELERATE DIAGNOSTICS, INC.
  (Registrant)
Date: August 8, 2019  
  /s/ Steve Reichling
  Steve Reichling
  Chief Financial Officer

 

     

 

EXHIBIT 3.1

 

AMENDED AND RESTATED BYLAWS

 

OF

 

ACCELERATE DIAGNOSTICS, INC.

 

(as amended and restated as of August 2, 2019)

 

     

 

 

ARTICLE I

Offices

 

Section 1.01        Registered Office. The registered office of Accelerate Diagnostics, Inc. (the “ Corporation ”) will be fixed in the Certificate of Incorporation of the Corporation (as amended, the “ Certificate of Incorporation ”).

 

Section 1.02        Other Offices. The Corporation may have other offices, both within and without the State of Delaware, as the board of directors of the Corporation (the “ Board of Directors ”) from time to time shall determine or the business of the Corporation may require.

 

ARTICLE II

Meetings of the Stockholders

 

Section 2.01         Place of Meetings. All meetings of the stockholders shall be held at such place, if any, either within or without the State of Delaware, or by means of remote communication, as shall be designated from time to time by resolution of the Board of Directors and stated in the notice of meeting.

 

Section 2.02         Annual Meeting. The annual meeting of the stockholders for the election of directors and for the transaction of such other business as may properly come before the meeting in accordance with these bylaws shall be held at such date, time, and place, if any, as shall be determined by the Board of Directors and stated in the notice of the meeting.

 

Section 2.03        Special Meetings .

 

(a)           Purpose. Special meetings of stockholders for any purpose or purposes shall be called only by:

 

(i)          the President or a Vice President (each, as defined in Section 4.01);

 

(ii)         the Board of Directors; or

 

(iii)        the Secretary (as defined in Section 4.01), following receipt of one or more written requests to call a special meeting of the stockholders in accordance with, and subject to, this Section 2.03 from stockholders of record who own, in the aggregate, at least 10% of the voting power of the outstanding shares of the Corporation then entitled to vote on the matter or matters to be brought before the proposed special meeting.

 

  1  

 

 

(b)           Notice. A request to the Secretary to call a special meeting of the stockholders shall be delivered to him or her at the Corporation’s principal executive offices and signed by each stockholder, or a duly authorized agent of such stockholder, requesting the special meeting and shall set forth:

 

(i)          a brief description of each matter of business desired to be brought before the special meeting;

 

(ii)         the reasons for conducting such business at the special meeting;

 

(iii)        the text of any proposal or business to be considered at the special meeting (including the text of any resolutions proposed to be considered and in the event that such business includes a proposal to amend these bylaws, the language of the proposed amendment); and

 

(iv)         the information required in Section 2.12(b) of these bylaws (for stockholder nomination demands) or Section 2.12(c) of these bylaws (for all other stockholder proposal demands), as applicable.

 

(c)           Business. Business transacted at a special meeting requested by stockholders shall be limited to the matters described in the special meeting request; provided, however, that nothing herein shall prohibit the Board of Directors from submitting matters to the stockholders at any special meeting requested by stockholders.

 

(d)           Time and Date . A special meeting requested by stockholders shall be held at such date and time as may be fixed by the Board of Directors; provided, however, that the date of any such special meeting shall be not more than 90 days after the request to call the special meeting is received by the Secretary. Notwithstanding the foregoing, a special meeting requested by stockholders shall not be held if:

 

(i)          the Board of Directors has called or calls for an annual or special meeting of the stockholders to be held within 90 days after the Secretary receives the request for the special meeting and the Board of Directors determines in good faith that the business of such meeting includes (among any other matters properly brought before the meeting) the business specified in the request;

 

(ii)         the stated business to be brought before the special meeting is not a proper subject for stockholder action under applicable law;

 

(iii)        an identical or substantially similar item (a “ Similar Item” ) was presented at any meeting of stockholders held within 120 days prior to the receipt by the Secretary of the request for the special meeting (and, for purposes of this Section 2.03(d)(iii), the election of directors shall be deemed a Similar Item with respect to all items of business involving the election or removal of directors);

 

  2  

 

 

(iv)         the special meeting request was made in a manner that involved a violation of Regulation 14A under the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder (the “ Exchange Act ”); or

 

(v)          if, in the good faith judgment of the Board of Directors, the purpose of the proposed meeting does not present a time sensitive issue that must be addressed before the next scheduled annual meeting.

 

(e)           Revocation . A stockholder may revoke a request for a special meeting at any time by written revocation delivered to the Secretary, and if, following such revocation, there are unrevoked requests from stockholders holding in the aggregate less than the requisite number of shares entitling the stockholders to request the calling of a special meeting, the Board of Directors, in its discretion, may cancel the special meeting.

 

Section 2.04         Adjournments. Any meeting of the stockholders, annual or special, may be adjourned from time to time to reconvene at the same or some other place, if any, and notice need not be given of any such adjourned meeting if the time, place, if any, thereof and the means of remote communication, if any, are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. If after the adjournment a new record date is fixed for stockholders entitled to vote at the adjourned meeting, the Board of Directors shall fix a new record date for notice of the adjourned meeting and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at the adjourned meeting as of the record date fixed for notice of the adjourned meeting.

 

Section 2.05         Notice of Meetings. Notice of the place (if any), date, hour, the record date for determining the stockholders entitled to vote at the meeting (if such date is different from the record date for stockholders entitled to notice of the meeting), and means of remote communication, if any, of every meeting of stockholders shall be given by the Corporation not less than 10 days nor more than 60 days before the meeting (unless a different time is specified by law) to every stockholder entitled to vote at the meeting as of the record date for determining the stockholders entitled to notice of the meeting. Notices of special meetings shall also specify the purpose or purposes for which the meeting has been called. Except as otherwise provided herein or permitted by applicable law, notice to stockholders shall be in writing and delivered personally or mailed to the stockholders at their address appearing on the books of the Corporation. Without limiting the manner by which notice otherwise may be given effectively to stockholders, notice of meetings may be given to stockholders by means of electronic transmission in accordance with applicable law. Notice of any meeting need not be given to any stockholder who shall, either before or after the meeting, submit a waiver of notice or who shall attend such meeting, except when the stockholder attends for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of the meeting shall be bound by the proceedings of the meeting in all respects as if due notice thereof had been given.

 

  3  

 

  

Section 2.06        List of Stockholders. The Corporation shall prepare a complete list of the stockholders entitled to vote at any meeting of stockholders ( provided, however, if the record date for determining the stockholders entitled to vote is less than 10 days before the date of the meeting, the list shall reflect the stockholders entitled to vote as of the 10th day before the meeting date), arranged in alphabetical order, and showing the address of each stockholder and the number of shares of capital stock of the Corporation registered in the name of each stockholder at least 10 days before any meeting of the stockholders. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at least 10 days before the meeting: (a) on a reasonably accessible electronic network, provided that the information required to gain access to such list was provided with the notice of the meeting; or (b) during ordinary business hours, at the principal place of business of the Corporation. If the meeting is to be held at a place, the list shall also be produced and kept at the time and place of the meeting the whole time thereof and may be inspected by any stockholder who is present. If the meeting is held solely by means of remote communication, the list shall also be open for inspection by any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting. Except as provided by applicable law, the stock ledger of the Corporation shall be the only evidence as to who are the stockholders entitled to examine the stock ledger and the list of stockholders or to vote in person or by proxy at any meeting of stockholders.

 

Section 2.07         Quorum. Unless otherwise required by law, the Certificate of Incorporation or these bylaws, at each meeting of the stockholders, one-third of the shares of the Corporation entitled to vote at the meeting, present in person or represented by proxy, shall constitute a quorum. If, however, such quorum shall not be present or represented at any meeting of the stockholders, the chair of the meeting or the stockholders entitled to vote thereat, present in person or represented by proxy, shall have power, by the affirmative vote of a majority in voting power thereof, to adjourn the meeting from time to time, in the manner provided in Section 2.04 until a quorum shall be present or represented. A quorum, once established, shall not be broken by the subsequent withdrawal of enough votes to leave less than a quorum. At any such adjourned meeting at which there is a quorum, any business may be transacted that might have been transacted at the meeting originally called.

 

Section 2.08        Organization . The Board of Directors may adopt by resolution such rules and regulations for the conduct of the meeting of the stockholders as it shall deem appropriate. At every meeting of the stockholders, the Chairman of the Board (as defined in Section 3.17), or in his or her absence or inability to act, the President, or, in his or her absence or inability to act, the officer or director whom the Board of Directors shall appoint, shall act as chair of, and preside at, the meeting. The Secretary or, in his or her absence or inability to act, the person whom the chair of the meeting shall appoint secretary of the meeting, shall act as secretary of the meeting and keep the minutes thereof. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the chair of any meeting of the stockholders shall have the right and authority to prescribe such rules, regulations, and procedures and to do all such acts as, in the judgment of such chair, are appropriate for the proper conduct of the meeting. Such rules, regulations, or procedures, whether adopted by the Board of Directors or prescribed by the chair of the meeting, may include, without limitation, the following:

 

  4  

 

  

(a)          the establishment of an agenda or order of business for the meeting;

 

(b)          the determination of when the polls shall open and close for any given matter to be voted on at the meeting;

 

(c)          rules and procedures for maintaining order at the meeting and the safety of those present;

 

(d)          limitations on attendance at or participation in the meeting to stockholders of record of the corporation, their duly authorized and constituted proxies, or such other persons as the chair of the meeting shall determine;

 

(e)          restrictions on entry to the meeting after the time fixed for the commencement thereof; and

 

(f)           limitations on the time allotted to questions or comments by participants.

 

Section 2.09        Voting; Proxies .

 

(a)           General . Unless otherwise required by law or provided in the Certificate of Incorporation, each stockholder shall be entitled to one vote, in person or by proxy, for each share of capital stock held by such stockholder.

 

(b)           Election of Directors. Unless otherwise required by the Certificate of Incorporation, the election of directors shall be by written ballot. If authorized by the Board of Directors, such requirement of a written ballot shall be satisfied by a ballot submitted by electronic transmission, provided that any such electronic transmission must be either set forth or be submitted with information from which it can be determined that the electronic transmission was authorized. Unless otherwise required by law, the Certificate of Incorporation, or these bylaws, the election of directors shall be decided by a plurality of the votes cast by the shares represented in person or by proxy at any meeting of stockholders held to elect directors and entitled to vote on such election of directors.

 

(c)          Other Matters. Unless otherwise required by law, the Certificate of Incorporation, or these bylaws, any matter, other than the election of directors, brought before any meeting of stockholders shall be decided by the affirmative vote of the majority of the votes cast by the shares present in person or represented by proxy at the meeting and entitled to vote on the matter.

 

  5  

 

 

(d)           Proxies. Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. Such authorization must be in writing and executed by the stockholder or his or her authorized officer, director, employee, or agent. To the extent permitted by law, a stockholder may authorize another person or persons to act for him or her as proxy by transmitting or authorizing the transmission of an electronic transmission to the person who will be the holder of the proxy or to a proxy solicitation firm, proxy support service organization, or like agent duly authorized by the person who will be the holder of the proxy to receive such transmission, provided that the electronic transmission either sets forth or is submitted with information from which it can be determined that the electronic transmission was authorized by the stockholder. A copy, facsimile transmission, or other reliable reproduction of a writing or transmission authorized by this Section 2.09(d) may be substituted for or used in lieu of the original writing or electronic transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile transmission, or other reproduction shall be a complete reproduction of the entire original writing or transmission. A proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke any proxy that is not irrevocable by attending the meeting and voting in person or by delivering to the Secretary a revocation of the proxy or a new proxy bearing a later date.

 

Section 2.10        Inspectors at Meetings of Stockholders. In advance of any meeting of the stockholders, the Board of Directors shall, appoint one or more inspectors, who may be employees of the Corporation, to act at the meeting or any adjournment thereof and make a written report thereof. The Board of Directors may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting, the person presiding at the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspector or inspectors may appoint or retain other persons or entities to assist the inspector or inspectors in the performance of their duties. In determining the validity and counting of proxies and ballots cast at any meeting of stockholders, the inspector or inspectors may consider such information as is permitted by applicable law. No person who is a candidate for office at an election may serve as an inspector at such election. When executing the duties of inspector, the inspector or inspectors shall:

 

(a)          ascertain the number of shares outstanding and the voting power of each;

 

(b)          determine the shares represented at the meeting and the validity of proxies and ballots;

 

(c)          count all votes and ballots;

 

(d)          determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors; and

 

(e)           certify their determination of the number of shares represented at the meeting and their count of all votes and ballots.

 

  6  

 

  

Section 2.11         Fixing the Record Date .  

 

(a)          In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor less than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the determination of stockholders entitled to notice of or to vote at the adjourned meeting.

 

(b)          In order that the Corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 10 days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. If no record date has been fixed by the Board of Directors, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting: (i) when no prior action by the Board of Directors is required by law, the record date for such purpose shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation and (ii) if prior action by the Board of Directors is required by law, the record date for such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.

 

(c)          In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion, or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.

 

  7  

 

  

Section 2.12         Advance Notice of Stockholder Nominations and Proposals .  

 

(a)           Annual Meetings . At a meeting of the stockholders, only such nominations of persons for the election of directors and such other business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, nominations or such other business must be:

 

(i)          specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors or any committee thereof;

 

(ii)         otherwise properly brought before the meeting by or at the direction of the Board of Directors or any committee thereof; or

 

(iii)        otherwise properly brought before an annual meeting by a stockholder who is a stockholder of record of the Corporation at the time such notice of meeting is delivered, who is entitled to vote at the meeting, and who complies with the notice procedures set forth in this Section 2.12.

 

In addition, any proposal of business (other than the nomination of persons for election to the Board of Directors) must be a proper matter for stockholder action. For business (including, but not limited to, director nominations) to be properly brought before an annual meeting by a stockholder pursuant to Section 2.12(a)(iii), the stockholder or stockholders of record intending to propose the business (the “ Proposing Stockholder ”) must have given timely notice thereof pursuant to this Section 2.12(a), in writing to the Secretary even if such matter is already the subject of any notice to the stockholders or Public Disclosure (as defined below) from the Board of Directors. To be timely, a Proposing Stockholder’s notice for an annual meeting must be delivered to or mailed and received at the principal executive offices of the Corporation: (x) not later than the close of business on the 90th day, nor earlier than the close of business on the 120th day, in advance of the anniversary of the previous year’s annual meeting if such annual meeting is to be held on a day which is not more than 30 days in advance of the anniversary of the previous year’s annual meeting or not later than 60 days after the anniversary of the previous year’s annual meeting; and (y) with respect to any other annual meeting of stockholders, including in the event that no annual meeting was held in the previous year, not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of: (1) the 90th day prior to such annual meeting and (2) the 10th day following the date of the first Public Disclosure of the date of such annual meeting. In no event shall the Public Disclosure of an adjournment or postponement of an annual meeting commence a new notice time period (or extend any notice time period). For the purposes of this Section 2.12, “ Public Disclosure ” shall mean a disclosure made in a press release reported by a national news service or in a document filed by the Corporation with the Securities and Exchange Commission (“ SEC ”) pursuant to Section 13, 14, or 15(d) of the Exchange Act.

 

  8  

 

  

(b)           Stockholder Nominations . For the nomination of any person or persons for election to the Board of Directors pursuant to Section 2.12(a)(iii) or Section 2.12(d), a Proposing Stockholder’s notice to the Secretary shall set forth or include:

 

(i)          the name, age, business address, and residence address of each nominee proposed in such notice;

 

(ii)         the principal occupation or employment of each such nominee;

 

(iii)        the class and number of shares of capital stock of the Corporation which are owned of record and beneficially by each such nominee (if any);

 

(iv)        such other information concerning each such nominee as would be required to be disclosed in a proxy statement soliciting proxies for the election of such nominee as a director in an election contest (even if an election contest is not involved) or that is otherwise required to be disclosed, under Section 14(a) of the Exchange Act;

 

(v)         a written questionnaire with respect to the background and qualification of such proposed nominee (which questionnaire shall be provided by the Secretary upon written request) and a written statement and agreement executed by each such nominee acknowledging that such person:

 

(A)         consents to being named in the Company’s proxy statement as a nominee and to serving as a director if elected;

 

(B)         intends to serve as a director for the full term for which such person is standing for election; and

 

(C)         makes the following representations: (1) that the director nominee has read and agrees to adhere to the Corporation’s Code of Ethics and any other of the Corporation’s policies or guidelines applicable to directors publicly available on the Corporation’s website, (2) that the director nominee is not and will not become a party to any agreement, arrangement, or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the Corporation, will act or vote on any issue or question (a “ Voting Commitment ”) that has not been disclosed to the Corporation or any Voting Commitment that could limit or interfere with such person’s ability to comply, if elected as a director of the Corporation, with such person’s fiduciary duties under applicable law, and (3) that the director nominee is not and will not become a party to any agreement, arrangement, or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement, or indemnification (“ Compensation Arrangement ”) that has not been disclosed to the Corporation in connection with such person’s nomination for director or service as a director.

 

  9  

 

  

(vi)        as to the Proposing Stockholder:

 

(A)          the name and address of the Proposing Stockholder as they appear on the Corporation’s books and of the beneficial owner, if any, on whose behalf the nomination is being made;

 

(B)         the class and number of shares of the Corporation which are owned by the Proposing Stockholder (beneficially and of record) and owned by the beneficial owner, if any, on whose behalf the nomination is being made, as of the date of the Proposing Stockholder’s notice;

 

(C)         a description of any agreement, arrangement, or understanding with respect to such nomination between or among the Proposing Stockholder or the beneficial owner, if any, on whose behalf the nomination is being made and any of their affiliates or associates, and any others (including their names) acting in concert with any of the foregoing;

 

(D)         a description of any agreement, arrangement, or understanding (including any derivative or short positions, profit interests, options, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of the Proposing Stockholder’s notice by, or on behalf of, the Proposing Stockholder or the beneficial owner, if any, on whose behalf the nomination is being made and any of their affiliates or associates, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of such person or any of their affiliates or associates with respect to shares of stock of the Corporation;

 

(E)         a representation that the Proposing Stockholder is a holder of record of shares of the Corporation entitled to vote at the meeting and intends to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice;

 

(F)         a representation whether the Proposing Stockholder intends to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation’s outstanding capital stock required to approve the nomination and/or otherwise to solicit proxies from stockholders in support of the nomination; and

 

(G)         a representation that the Proposing Stockholder will notify the Corporation in writing with any update or supplement to the information required in this Section 2.12(b)(vi) as of the record date for the annual meeting within 5 business days after the record date for such meeting.

 

  10  

 

  

The Corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as an independent director of the Corporation or that could be material to a reasonable stockholder’s understanding of the independence, or lack thereof, of such nominee.

 

(c)           Other Stockholder Proposals . For all business other than director nominations, a Proposing Stockholder’s notice to the Secretary shall set forth as to each matter the Proposing Stockholder proposes to bring before the annual meeting:

 

(i)          a brief description of the business desired to be brought before the annual meeting;

 

(ii)         the reasons for conducting such business at the annual meeting;

 

(iii)        the text of any proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend these bylaws, the language of the proposed amendment);

 

(iv)        any substantial interest (within the meaning of Item 5 of Schedule 14A under the Exchange Act) in such business of such stockholder and the beneficial owner (within the meaning of Section 13(d) of the Exchange Act), if any, on whose behalf the business is being proposed;

 

(v)         any other information relating to such stockholder and beneficial owner, if any, on whose behalf the proposal is being made, required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for the proposal and pursuant to and in accordance with Section 14(a) of the Exchange Act and the rules and regulations promulgated thereunder;

 

(vi)        a description of all agreements, arrangements, or understandings between or among such stockholder, the beneficial owner, if any, on whose behalf the proposal is being made, any of their affiliates or associates, and any other person or persons (including their names) in connection with the proposal of such business and any material interest of such stockholder, beneficial owner, or any of their affiliates or associates, in such business, including any anticipated benefit therefrom to such stockholder, beneficial owner, or their affiliates or associates; and

 

(vii)       the information required by Section 2.12(b)(vi) above.

 

  11  

 

  

(d)           Special Meetings of Stockholders . Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation’s notice of meeting. Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders called by the Board of Directors at which directors are to be elected pursuant to the Corporation’s notice of meeting:

 

(i)          by or at the direction of the Board of Directors or any committee thereof; or

 

(ii)         provided that the Board of Directors has determined that directors shall be elected at such meeting, by any stockholder of the Corporation who is a stockholder of record at the time the notice provided for in this Section 2.12(d) is delivered to the Secretary, who is entitled to vote at the meeting, and upon such election and who complies with the notice procedures set forth in this Section 2.12.

 

In the event the Corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board of Directors, any such stockholder entitled to vote in such election of directors may nominate a person or persons (as the case may be) for election to such position(s) as specified in the Corporation’s notice of meeting, if such stockholder delivers a stockholder’s notice that complies with the requirements of Section 2.12(b) to the Secretary at its principal executive offices not earlier than the close of business on the 120th day prior to such special meeting and not later than the close of business on the later of: (x) the 90th day prior to such special meeting; or (y) the 10th day following the date of the first Public Disclosure of the date of such special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting. In no event shall the Public Disclosure of an adjournment or postponement of a special meeting commence a new time period (or extend any notice time period).

 

(e)           Effect of Noncompliance . Only such persons who are nominated in accordance with the procedures set forth in this Section 2.12 shall be eligible to be elected at any meeting of stockholders of the Corporation to serve as directors and only such other business shall be conducted at a meeting as shall be brought before the meeting in accordance with the procedures set forth in this Section 2.12. If any proposed nomination or other business was not made or proposed in compliance with this Section 2.12, then except as otherwise required by law, the chair of the meeting shall have the power and duty to declare that such nomination shall be disregarded or that such proposed other business shall not be transacted.

 

(f)            Rule 14a-8. This Section 2.12 shall not apply to a proposal proposed to be made by a stockholder if the stockholder has notified the Corporation of the stockholder’s intention to present the proposal at an annual or special meeting only pursuant to and in compliance with Rule 14a-8 under the Exchange Act and such proposal has been included in a proxy statement that has been prepared by the Corporation to solicit proxies for such meeting.

 

  12  

 

  

Section 2.13        Written Consent of Stockholders Without a Meeting. Any action to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action to be so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation. Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within 60 days of the earliest dated consent delivered in the manner required by this Section 2.13, written consents signed by a sufficient number of holders to take action are delivered to the Corporation. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall, to the extent required by applicable law, be given to those stockholders who have not consented in writing, and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for notice of such meeting had been the date that written consents signed by a sufficient number of holders to take the action were delivered to the Corporation.

 

ARTICLE III

Board of Directors

 

Section 3.01         General Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. The Board of Directors may adopt such rules and procedures, not inconsistent with the Certificate of Incorporation, these bylaws, or applicable law, as it may deem proper for the conduct of its meetings and the management of the Corporation.

 

Section 3.02         Number; Term of Office. The Board of Directors shall consist of not less than three and not more than ten directors as fixed from time to time by resolution adopted by the Board of Directors. Each director shall hold office until a successor is duly elected and qualified or until the director’s earlier death, resignation, disqualification, or removal.

 

Section 3.03         Newly Created Directorships and Vacancies. Any newly created directorships resulting from an increase in the authorized number of directors and any vacancies occurring in the Board of Directors, may be filled by the affirmative votes of a majority of the remaining members of the Board of Directors, although less than a quorum, or by a sole remaining director. A director so elected shall be elected to hold office until the earlier of the expiration of the term of office of the director whom he or she has replaced, a successor is duly elected and qualified, or the earlier of such director’s death, resignation, or removal.

 

Section 3.04         Resignation. Any director may resign at any time by notice given in writing or by electronic transmission to the Corporation. Such resignation shall take effect at the date of receipt of such notice by the Corporation or at such later effective date or upon the happening of an event or events as is therein specified. A verbal resignation shall not be deemed effective until confirmed by the director in writing or by electronic transmission to the Corporation.

 

  13  

 

  

Section 3.05        Removal. Except as prohibited by applicable law or the Certificate of Incorporation, the stockholders holding a majority of the shares then entitled to vote at an election of directors may remove any director from office with or without cause.

 

Section 3.06         Fees and Expenses. Directors shall receive such fees for their services on the Board of Directors and any committee thereof and such reimbursement of their expenses as may be fixed or determined by the Board of Directors.

 

Section 3.07         Regular Meetings. Regular meetings of the Board of Directors may be held without notice at such times and at such places as may be determined from time to time by the Board of Directors.

 

Section 3.08         Special Meetings. Special meetings of the Board of Directors may be called by the President, the Chairman of the Board or any two directors, and shall be held at such place, on such date and at such time as they, or he or she shall fix. Notice of each such special meeting shall be given to each director not less than 24 hours before the meeting by one of the means specified in Section 3.11 hereof other than by mail, or on at least three days’ notice if given by mail. The notice need not state the purposes of the special meeting and, unless indicated in the notice thereof, any and all business may be transacted at a special meeting.

 

Section 3.09         Telephone Meetings. Board of Directors or Board of Directors committee meetings may be held by means of telephone conference or other communications equipment by means of which all persons participating in the meeting can hear each other and be heard. Participation by a director in a meeting pursuant to this Section 3.09 shall constitute presence in person at such meeting.

 

Section 3.10         Adjourned Meetings. A majority of the directors present at any meeting of the Board of Directors, including an adjourned meeting, whether or not a quorum is present, may adjourn and reconvene such meeting to another time and place. At least 24 hours’ notice of any adjourned meeting of the Board of Directors shall be given to each director whether or not present at the time of the adjournment, if such notice shall be given by one of the means specified in Section 3.11 hereof other than by mail, or at least three days’ notice if by mail. Any business may be transacted at an adjourned meeting that might have been transacted at the meeting as originally called.

 

Section 3.11         Notices. Subject to Section 3.08, Section 3.10, and Section 3.12 hereof, whenever notice is required to be given to any director by applicable law, the Certificate of Incorporation or these bylaws, such notice shall be deemed given effectively if given in person or by telephone, mail addressed to such director at such director’s address as it appears on the records of the Corporation, facsimile, e-mail or by other means of electronic transmission.

 

  14  

 

  

Section 3.12         Waiver of Notice. Whenever notice to directors is required by applicable law, the Certificate of Incorporation, or these bylaws, a waiver thereof, in writing signed by, or by electronic transmission by, the director entitled to the notice, whether before or after such notice is required, shall be deemed equivalent to notice. Attendance by a director at a meeting shall constitute a waiver of notice of such meeting except when the director attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business on the ground that the meeting was not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special Board of Directors or committee meeting need be specified in any waiver of notice.

 

Section 3.13        Organization. At each regular or special meeting of the Board of Directors, the Chairman of the Board or, in his or her absence, the President or, in his or her absence, another director or officer selected by the Board of Directors shall preside. The Secretary shall act as secretary at each meeting of the Board of Directors. If the Secretary is absent from any meeting of the Board of Directors, an assistant secretary of the Corporation shall perform the duties of secretary at such meeting; and in the absence from any such meeting of the Secretary and all assistant secretaries of the Corporation, the person presiding at the meeting may appoint any person to act as secretary of the meeting.

 

Section 3.14         Quorum of Directors. Except as otherwise provided by these bylaws, the Certificate of Incorporation, or required by applicable law, the presence of a majority of the total number of directors on the Board of Directors shall be necessary and sufficient to constitute a quorum for the transaction of business at any meeting of the Board of Directors.

 

Section 3.15         Action by Majority Vote. Except as otherwise provided by these bylaws, the Certificate of Incorporation, or required by applicable law, the vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors.

 

Section 3.16         Action Without Meeting. Unless otherwise restricted by the Certificate of Incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting if all directors or members of such committee, as the case may be, consent thereto in writing or by electronic transmission, and the writings or electronic transmissions are filed with the minutes of proceedings of the Board of Directors or committee in accordance with applicable law.

 

Section 3.17        Chairman of the Board. The Board of Directors, in its discretion, may select one of its members to be its chair (the “ Chairman of the Board ”) and shall fill any vacancy in the position of Chairman of the Board at such time and in such manner as the Board of Directors shall determine. Except as otherwise provided in these bylaws, the Chairman of the Board shall preside at all meetings of the Board of Directors and of stockholders at which he or she is present. The Chairman of the Board shall, subject to the direction of the Board of Directors, have general supervision over the affairs of the Corporation, and shall, from time to time, consult and advise with the President in the direction and management of the Corporation’s business and affairs, and shall also do and perform such other duties as may, from time to time, be assigned to him by the Board of Directors.

 

  15  

 

  

Section 3.18         Committees of the Board of Directors. The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. If a member of a committee shall be absent from any meeting, or disqualified from voting thereat, the remaining member or members present at the meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent permitted by applicable law, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it to the extent so authorized by the Board of Directors. Unless the Board of Directors provides otherwise, at all meetings of such committee, a majority of the then authorized members of the committee shall constitute a quorum for the transaction of business, and the vote of a majority of the members of the committee present at any meeting at which there is a quorum shall be the act of the committee. Each committee shall keep regular minutes of its meetings. Unless the Board of Directors provides otherwise, each committee designated by the Board of Directors may make, alter and repeal rules and procedures for the conduct of its business. In the absence of such rules and procedures each committee shall conduct its business in the same manner as the Board of Directors conducts its business pursuant to this ARTICLE III.

 

ARTICLE IV

Officers

 

Section 4.01         Positions and Election. The officers of the Corporation shall be chosen by the Board of Directors and shall include a chief executive officer (the “ Chief Executive Officer” ), a president (the “ President ”), a chief financial officer (the “ Chief Financial Officer ”), a treasurer (the “ Treasurer ”), and a secretary (the “ Secretary ”). The Board of Directors, in its discretion, may also elect one or more vice presidents, assistant treasurers, assistant secretaries, and other officers in accordance with these bylaws. Any two or more offices may be held by the same person.

 

Section 4.02         Term. Each officer of the Corporation shall hold office until such officer’s successor is elected and qualified or until such officer’s earlier death, resignation, or removal. Any officer elected or appointed by the Board of Directors may be removed by the Board of Directors at any time with or without cause by the majority vote of the members of the Board of Directors then in office. The removal of an officer shall be without prejudice to his or her contract rights, if any. The election or appointment of an officer shall not of itself create contract rights. Any officer of the Corporation may resign at any time by giving written notice of his or her resignation to the President or the Secretary. Any such resignation shall take effect at the time specified therein or, if the time when it shall become effective shall not be specified therein, immediately upon its receipt. Unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective. Should any vacancy occur among the officers, the position shall be filled for the unexpired portion of the term by appointment made by the Board of Directors.

 

  16  

 

  

Section 4.03        President. The President shall, subject to the direction and supervision of the Board of Directors, be the Chief Executive Officer of the Corporation and shall have general and active control of its affairs and business and general supervision of its officers, agents and employees. The President shall have such powers and perform such duties as from time to time may be assigned or delegated to the President by the Board of Directors or that are incident to the office of president or chief executive officer.

 

Section 4.04        Vice Presidents. Each vice president of the Corporation shall have such powers and perform such duties as from time to time may be assigned or delegated to such vice president by the Board of Directors or the President or that are incident to the office of vice president.

 

Section 4.05        Secretary. The Secretary shall attend all sessions of the Board of Directors and all meetings of the stockholders and record all votes and the minutes of all proceedings in a book to be kept for that purpose, and shall perform like duties for committees of the Board of Directors when required. The Secretary shall give, or cause to be given, notice of all meetings of the stockholders and meetings of the Board of Directors, and shall have such powers and perform such duties as from time to time may be assigned or delegated to the Secretary by the Board of Directors or the President or that are incident to the office of secretary. The Secretary shall keep in safe custody the seal of the Corporation and have authority to affix the seal to all documents requiring it and attest to the same.

 

Section 4.06        Chief Financial Officer. The Chief Financial Officer shall be the principal financial officer of the Corporation and shall have such powers and perform such duties as from time to time may be assigned or delegated to the Chief Financial Officer by the Board of Directors or the President or that are incident to the office of chief financial officer.

 

Section 4.07        Treasurer. The Treasurer shall have the custody of the Corporation’s funds and securities, except as otherwise provided by the Board of Directors, and shall keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation and shall deposit all moneys and other valuable effects in the name and to the credit of the Corporation in such depositories as may be designated by the Board of Directors. The Treasurer shall disburse the funds of the Corporation as may be ordered by the Board of Directors, taking proper vouchers for such disbursements, and shall render to the President and the directors, at the regular meetings of the Board of Directors, or whenever they may require it, an account of all his or her transactions as treasurer and of the financial condition of the Corporation. The Treasurer shall have such powers and perform such duties as from time to time may be assigned or delegated to the Treasurer by the Board of Directors or the President or that are incident to the office of treasurer.

 

Section 4.08         Other Officers. Such other officers as the Board of Directors may choose shall perform such duties and have such powers as from time to time may be assigned to them by the Board of Directors or the President. The Board of Directors may delegate to any other officer of the Corporation the power to choose such other officers and to prescribe their respective duties and powers.

 

  17  

 

  

Section 4.09        Duties of Officers May Be Delegated. In case any officer is absent, or for any other reason that the Board of Directors may deem sufficient, the President or the Board of Directors may delegate for the time being the powers or duties of such officer to any other officer or to any director.

 

Section 4.10         Execution Authority. All contracts of the Corporation shall be executed on behalf of the Corporation by: (a) the President or any vice president of the Corporation; (b) such other officer or employee of the Corporation authorized in writing by the President, with such limitations or restrictions on such authority as he or she deems appropriate; or (c) such other person as may be authorized by the Board of Directors, and, if required, the seal of the Corporation shall be thereto affixed and attested by the Secretary or an assistant secretary of the Corporation.

 

ARTICLE V

INDEMNIFICATION

 

Section 5.01        Indemnification. The Corporation shall indemnify, advance expenses, and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person (a “ Covered Person ”) who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “ Proceeding ”), by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or nonprofit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys’ fees) reasonably incurred by such Covered Person. Notwithstanding the preceding sentence, except for claims for indemnification (following the final disposition of such Proceeding) or advancement of expenses not paid in full, the Corporation shall be required to indemnify a Covered Person in connection with a Proceeding (or part thereof) commenced by such Covered Person only if the commencement of such Proceeding (or part thereof) by the Covered Person was authorized in the specific case by the Board of Directors of the Corporation.

 

Section 5.02        Non-Exclusivity of Rights. The rights conferred on any person by this ARTICLE V will not be exclusive of any other right which such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, these bylaws, agreement, vote of stockholders or disinterested directors, or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding office. The Corporation is specifically authorized to enter into individual contracts with any or all of its directors or officers respecting indemnification and advances, to the fullest extent not prohibited by applicable law.

 

  18  

 

  

Section 5.03        Other Indemnification. The Corporation’s obligation, if any, to indemnify any person who was or is serving at its request as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, enterprise, or nonprofit entity shall be reduced by any amount such person may collect as indemnification from such other corporation, partnership, joint venture, trust, enterprise, or nonprofit entity.

 

Section 5.04        Insurance. The Corporation may purchase and maintain insurance on behalf of any person who is or was a director or officer of the Corporation, or is or was serving at the request of Corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, enterprise, or nonprofit entity against any liability asserted against him or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the Corporation would have the power to indemnify him or her against such liability under applicable law.

 

Section 5.05        Repeal, Amendment, or Modification. Any amendment, repeal, or modification of this ARTICLE V shall not adversely affect any right or protection hereunder of any person in respect of any act or omission occurring prior to the time of such repeal or modification.

 

ARTICLE VI

Stock Certificates and Their Transfer

 

Section 6.01         Certificates Representing Shares. The shares of stock of the Corporation shall be represented by certificates; provided that the Board of Directors may provide by resolution or resolutions that some or all of any class or series shall be uncertificated shares that may be evidenced by a book-entry system maintained by the registrar of such stock. If shares are represented by certificates, such certificates shall be in the form, other than bearer form, approved by the Board of Directors. The certificates representing shares of stock shall be signed by, or in the name of, the Corporation by any two authorized officers of the Corporation. Any or all such signatures may be facsimiles. Although any officer, transfer agent, or registrar whose manual or facsimile signature is affixed to such a certificate ceases to be such officer, transfer agent, or registrar before such certificate has been issued, it may nevertheless be issued by the Corporation with the same effect as if such officer, transfer agent, or registrar were still such at the date of its issue.

 

Section 6.02         Transfers of Stock. Stock of the Corporation shall be transferable in the manner prescribed by law and in these bylaws. Transfers of stock shall be made on the books administered by or on behalf of the Corporation only by the direction of the registered holder thereof or such person’s attorney, lawfully constituted in writing, and, in the case of certificated shares, upon the surrender to the Company or its transfer agent or other designated agent of the certificate thereof, which shall be cancelled before a new certificate or uncertificated shares shall be issued.

 

Section 6.03         Transfer Agents and Registrars. The Board of Directors may appoint, or authorize any officer or officers to appoint, one or more transfer agents and one or more registrars.

 

  19  

 

  

Section 6.04         Lost, Stolen, or Destroyed Certificates. The Board of Directors or the Secretary may direct a new certificate or uncertificated shares to be issued in place of any certificate theretofore issued by the Corporation alleged to have been lost, stolen, or destroyed upon the making of an affidavit of that fact by the owner of the allegedly lost, stolen, or destroyed certificate. When authorizing such issue of a new certificate or uncertificated shares, the Board of Directors or the Secretary may, in its discretion and as a condition precedent to the issuance thereof, require the owner of the lost, stolen, or destroyed certificate, or the owner’s legal representative to give the Corporation a bond sufficient to indemnify it against any claim that may be made against the Corporation with respect to the certificate alleged to have been lost, stolen, or destroyed or the issuance of such new certificate or uncertificated shares.

 

ARTICLE VII

General Provisions

 

Section 7.01         Seal. The seal of the Corporation shall be in such form as shall be approved by the Board of Directors. The seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise, as may be prescribed by law or custom or by the Board of Directors.

 

Section 7.02         Fiscal Year. The Board of Directors shall have the power to fix, and from time to time change, the fiscal year of the Corporation. Unless otherwise fixed by the Board of Directors, the fiscal year shall be from January 1 st to December 31 st of each year.

 

Section 7.03         Checks, Notes, Drafts, Etc. All checks, notes, drafts, or other orders for the payment of money of the Corporation shall be signed, endorsed, or accepted in the name of the Corporation by such officer, officers, person, or persons as from time to time may be designated by the Board of Directors or by an officer or officers authorized by the Board of Directors to make such designation.

 

Section 7.04         Conflict with Applicable Law or Certificate of Incorporation. These bylaws are adopted subject to any applicable law and the Certificate of Incorporation. Whenever these bylaws may conflict with any applicable law or the Certificate of Incorporation, such conflict shall be resolved in favor of such law or the Certificate of Incorporation.

 

Section 7.05        Books and Records. Any records administered by or on behalf of the Corporation in the regular course of its business, including its stock ledger, books of account, and minute books, may be maintained on any information storage device, method, or one or more electronic networks or databases (including one or more distributed electronic networks or databases); provided that the records so kept can be converted into clearly legible paper form within a reasonable time, and, with respect to the stock ledger, the records so kept comply with applicable law. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant to applicable law.

 

  20  

 

  

Section 7.06        Forum for Adjudication of Disputes. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for:

 

(a)          any derivative action or proceeding brought on behalf of the Corporation;

 

(b)          any action asserting a claim for breach of a fiduciary duty owed by any director, officer, employee, or agent of the Corporation to the Corporation or the Corporation’s stockholders;

 

(c)          any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, the Certificate of Incorporation, or these bylaws; or

 

(d)          any action asserting a claim governed by the internal affairs doctrine;

 

in each case, subject to said court having personal jurisdiction over the indispensable parties named as defendants therein. If any action the subject matter of which is within the scope of this Section 7.06 is filed in a court other than a court located within the State of Delaware (a “ Foreign Action ”) in the name of any stockholder, such stockholder shall be deemed to have consented to: (i) the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce this Section 7.06 (an “ Enforcement Action ”); and (ii) having service of process made upon such stockholder in any such Enforcement Action by service upon such stockholder’s counsel in the Foreign Action as agent for such stockholder. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section 7.06.

 

ARTICLE VIII

Amendments

 

In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the Board of Directors is expressly authorized to adopt, alter, or repeal these bylaws. The stockholders shall also have power to adopt, alter, or repeal these bylaws; provided, however, that any proposal by a stockholder to amend these bylaws will be subject to the provisions of ARTICLE II of these bylaws except as otherwise required by law.

 

  21  

 

EXHIBIT 10.1

 

 

August 6, 2019

 

John J. Phillips

[ADDRESS OMITTED]

 

Delivered Electronically via Email

 

Re: Offer of Employment

 

Dear Jack:

 

Congratulations! We are delighted to enter into this Letter Agreement (the “ Agreement ”) to memorialize the terms under which you will serve as Chief Operating Officer of Accelerate Diagnostics, Inc. (the “ Company ”). You will initially join us on a part-time basis and then transition to a full-time employee of the Company.

 

Your start date as a part-time employee of the Company will be August 6, 2019 (the “ Part-Time Start Date ”) and your full-time employment with the Company will commence on September 1, 2019 (the “ Full-Time Start Date ”). Once this Agreement becomes effective, it will form the entire agreement between you and the Company with respect to the matters described in this Agreement and it will supersede and replace any prior understandings (whether oral or written) with respect to the subject matter described herein. If you have any questions about the information below, please contact me directly.

 

Provision   Agreement
     
Location:   Your principal place of employment will be the Company’s principal executive offices in Tucson, Arizona.  This offer is contingent upon you relocating to Tucson, Arizona before August 31, 2020.
     
Title; Reporting; Duties;    
No Conflicts:   Beginning on the Part-Time Start Date, you will serve as the Chief Operating  Officer of the Company, reporting directly to the President and Chief Executive Officer of the Company.  While serving as a part-time employee, you will perform those duties, abide by those restrictions, and have those responsibilities set forth on Exhibit A .
     
    Beginning on the Full-Time Start Date, you will continue to report directly to the President and Chief Executive Officer of the Company, and assume control over, and responsibility for, the day-to-day operations of the Company and shall have such other duties, authorities and responsibilities commensurate for such or a similar position at a similarly-situated company and such additional duties as may be assigned to you by the President and Chief Executive Officer from time to time.

 

     

 

 

Jack Phillips

August 6, 2019

Page 2

 

    Beginning on the Full-Time Start Date, you understand that: (i) your employment services will be full-time and exclusive to the Company and that you will be expected to devote substantially all of your full business time, attention, energy and skills to the Company; (ii) you agree to serve the Company faithfully, loyally, honestly and to the best of your ability; and (iii) you will not, without the express written consent of the Board, engage in any other commercial activity or outside employment.
     
    The preceding paragraph is not intended to prohibit you from engaging in charitable or nonprofessional activities such as personal investments or conducting private business affairs, as long as they do not conflict or interfere with the performance of your duties to the Company. You agree to observe and comply with the Company’s rules and policies, as the same may be adopted and amended from time to time.
     
    By signing this Agreement, you represent and warrant that you are under no contractual or other obligations or commitments that are inconsistent with your obligations under this Agreement, including, without limitation, any restrictions that would preclude you from providing services to the Company ( e.g ., a non-compete with a former employer).
     
Base Salary:   A rate of $495,000 per year (the “ Base Salary ”) to be paid according to the Company’s normal payroll cycle (which Base Salary will be pro-rated during the period you are serving as a part-time employee).  Your Base Salary will be reviewed at least annually and may be adjusted upward or downward by the Compensation Committee of the Board of Directors (the “ Compensation Committee ”) in its sole discretion. On or before December 31, 2019 the Compensation Committee will consider establishing a deferred compensation program to allow you and other members of senior management to defer a portion of compensation earned in 2020 and future calendar years (“ Deferred Compensation Plan ”). The Deferred Compensation Plan, if any, will be structured in a manner that complies with Section 409A of the Internal Revenue Code which means, among other things, that deferral elections must be completed before December 31 of the year immediately preceding the year for which the compensation will be earned.
     
Sign-On Cash Bonus:   Within 30 days of the Part-Time Start Date, you will receive a signing bonus equal to $100,000 (“ Signing Bonus ”). The Signing Bonus will be paid to you in a single sum cash payment. If, prior to the 24 month anniversary of the Full-Time Start Date, you are terminated for Cause (as defined in Exhibit B ) or voluntarily resign your employment (except for Good Reason (as defined in Exhibit B )), you will be required to repay the Signing Bonus on a monthly pro-rata basis ( e.g. , every full month of employment reduces your potential repayment amount by 1/24 th ).

 

     

 

  

Jack Phillips

August 6, 2019

Page 3

 

Sign-On Option Grant:   On your Part-Time Start Date you will be awarded a non-qualified stock option under our 2012 Omnibus Equity Incentive Plan, as amended (the “ Equity Plan ”) to purchase 1,249,917 shares of common stock of the Company (the “ Option ”), with such Option carrying an exercise price per share equal to the closing price for the stock as reported on the Nasdaq Stock Market (“ Nasdaq ”) on the trading date immediately preceding the date of grant.  The Option will be subject to a time-based vesting schedule as follows: (i) 40% will vest on the second anniversary of the date of grant; and (ii) the remaining 60% will vest in 36 equal monthly installments over the subsequent 36 months. The Option will be subject to such other terms and conditions specified by the Compensation Committee, the Equity Plan, the award agreement that you must execute as a condition of the grant, and the Company’s insider trading policy. The form of Nonqualified Stock Option Agreement to be used for the Option is attached hereto as Exhibit C.
     
Reimbursement for    
Relocation Expenses:   We will reimburse you up to $200,000 of expenses incurred in connection with your relocation to the Tucson metropolitan area. To obtain reimbursement you must submit your expenses promptly, in accordance with Company policy, with appropriate supporting documentation, and such expenses will be reimbursed no later than the last day of the tax year following the tax year in which the expense was incurred. If, prior to the 24 month anniversary of the Full-Time Start Date, you are terminated for Cause or voluntarily resign your employment (except for Good Reason), you will be required to repay any previously reimbursed relocation expenses on a monthly pro-rata basis ( e.g. , every full month of employment reduces your potential repayment amount by 1/24 th ).
     
Temporary Housing and    
Air Travel:   In addition to the expense reimbursement described above, for expenses incurred for up to 18 months following the Part-Time Start Date, the Company will reimburse you for reasonable and customary temporary housing costs in the Tucson metropolitan area and airfare between Arizona and Indiana for you and your spouse (with such reimbursement also applying to any such expenses incurred during the one month period preceding the Part-Time Start Date). To obtain reimbursement you must submit your expenses promptly, in accordance with Company policy, with appropriate supporting documentation, and such expenses will be reimbursed no later than the last day of the tax year following the tax year in which the expense was incurred.
     
Non-Compensatory    
Investment in Company:   You have indicated that you would like to make a $1,000,000 investment into the Company’s common stock. Following your acceptance of this Agreement, we will present you with a Subscription Agreement pursuant to which you may, in your sole and absolute discretion, agree to purchase $1,000,000 of the Company’s common stock at the applicable prevailing market price in accordance with Nasdaq rules.  Such non-compensatory transaction will be structured to comply with Rule 506(b) of Regulation D promulgated under the Securities Act of 1933, as amended, and will otherwise be structured to comply with all applicable laws, rules and regulations including, without limitation, Nasdaq rules.

 

     

 

 

Jack Phillips

August 6, 2019

Page 4

 

Annual Incentive    
Opportunity:   Beginning January 1, 2020 and for each full calendar year during the Term thereafter, you will be eligible to participate in an annual cash incentive program adopted in writing and approved by the Compensation Committee (the “ AIP ”).  Your target incentive under the AIP will equal 100% of your Base Salary (as of the first day of the calendar year or February 1 of the calendar year, whichever is greater), and in no event will your AIP payment exceed 150% of your Base Salary (as of the first day of the calendar year or February 1 of the calendar year, whichever is greater). Whether you are entitled to receive an AIP payment, and the amount of such payment, will depend on the attainment of written quantitative and qualitative performance goals, including financial performance goals, establish by the Compensation Committee in its sole discretion. The amount of the AIP, if any, will be certified by the Compensation Committee in January or February of the year following the year to which the AIP relates, and the earned AIP, if any, will be paid to you no later than March 15 of the year following the year to which the AIP relates ( e.g. , the AIP for 2020, if any, will be paid no later than March 15, 2021).  Except as set forth below, you must be employed by the Company through the date the AIP is paid in order to earn and be eligible to receive the AIP.
     
Long-Term Incentive    
Compensation:   Beginning January 1, 2021 and for each full calendar year during the Term thereafter, you will be eligible to receive grants of stock options, performance shares and other awards under the Equity Plan (the “ Equity Awards ”).  The amount of Equity Awards, the mix of Equity Awards, the vesting schedule and the other terms and conditions of the Equity Awards will be established by the Compensation Committee in its sole discretion, provided, that, for the 2021 calendar year your Equity Award grant will equal 400% of your then Base Salary and will consist of an award mix of 50% non-qualified stock options and 50% performance shares. The Equity Awards will be subject to such other terms and conditions specified by the Compensation Committee, the Equity Plan, the award agreement that you must execute as a condition of the grant(s), and the Company’s insider trading policy.
     
Benefits; Vacation:   During the Term, you will be eligible to participate in the Company’s standard company benefit and vacation plans, as such plans may be amended, modified, or terminated by the Company from time to time, with or without notice, in accordance with the applicable benefit and vacation plan documents. For the avoidance of doubt, your participation in such plans will be subject to the terms and conditions set forth in the applicable benefit plan documents.  The Company will reimburse you for any costs associated with your election and purchase of COBRA under your prior employer’s group medical plan beginning August 1, 2019 and for up to two (2) months thereafter. In light of your transition to full-time employment effective September 1, 2019, your participation in the Company’s medical plan will begin on September 1, 2019.

 

     

 

 

Jack Phillips

August 6, 2019

Page 5

 

Term:   Your employment with the Company is at-will and either you or the Company may terminate your employment at any time and for any reason, with or without Cause (as defined in Exhibit B ), in each case subject to the terms and provisions of this Agreement. The initial term of your employment under this Agreement shall commence on the Part-Time Start Date and shall continue until the two (2) year anniversary of the Full-Time Start Date (the “ Initial Term ”). The Initial term will automatically extend on the same terms and conditions set forth below for additional one (1) year periods (each a “ Renewal Term ”), unless either party gives the other party written notice of non-renewal at least 30 days prior to the end of the Initial Term or any Renewal Term. The Initial Term, together with all Renewal Terms, are collectively referred to in this Agreement as the “ Term .”
     
    Unless otherwise indicated in a writing to you from the Board of Directors (the “ Board ”), upon your termination of employment with Company for any reason, and without any further action on your part, you will be deemed to immediately resign all other officerships, directorships, managerships, and other positions you hold with the Company and its affiliates. If for any reason this provision is determined to be insufficient to effectuate such resignations, you agree to sign any documents or instruments the Company determines necessary to effectuate such resignations.
     
Termination    
of Employment:   This Agreement, and your employment hereunder, may be terminated at any time, for any reason, by you or the Company upon at least 30 days prior written notice, provided, that, the Company may terminate your employment immediately for Cause.  Upon your termination for any reason, the Company will pay you your accrued but unpaid Base Salary through your date of termination and any accrued but unpaid reasonable business expenses through your date of termination (the “ Accrued Obligations ”), with such amount paid in compliance in accordance with applicable law. In addition to the Accrued Obligations, you may be entitled to receive severance benefits and Equity Award acceleration as described below.
     
Death or Disability:   This Agreement, and your employment hereunder, will terminate immediately upon your death or Disability (as defined in Exhibit B ). In such case, you (or your spouse or estate) will be entitled to the Accrued Obligations.
     
Termination and    
Severance Prior to    
a Change of Control:   In the event your full-time employment is terminated by the Company without Cause or by you with Good Reason (as defined in Exhibit B ) prior to a Change of Control (as defined in Exhibit B ), then, in addition to the Accrued Obligations, and subject to your timely execution (and non-revocation) of the release described below, you will be entitled to receive a cash severance payment equal to the sum of: (i) 12 months of your then Base Salary; and (ii) your average earned AIP for over the Term (collectively, the “ Base Severance Amount ”). The Base Salary Severance Amount will be paid to you in installments over a 12-month period, in accordance with the Company’s normal payroll cycle, with the first installment paid during the first payroll period following the expiration of the release revocation period described below. In addition to the Base Severance Amount, you will be entitled to receive a pro-rata AIP for the year in which your termination occurred, with such pro-rata AIP paid at the same time described above.

 

     

 

 

Jack Phillips

August 6, 2019

Page 6

 

Full Vesting of Equity Awards    
on Change of Control:   Upon the closing of a transaction that results in a Change of Control, and notwithstanding anything in the Equity Plan to the contrary, your Option and other Equity Awards shall fully vest and become exercisable.
     
Termination and    
Severance Following    
a Change of Control:   In the event your full-time employment is terminated by the Company without Cause or by you with Good Reason (as defined in Exhibit B ) during the 12 month period following a Change of Control, then, in addition to the Accrued Obligations, and subject to your timely execution (and non-revocation) of the release described below, you will be entitled receive a cash severance payment equal to the sum of: (i) 18 months of your then Base Salary; and (ii) 18 times the monthly amount that is charged to COBRA qualified beneficiaries for the same medical coverage options elected by you immediately prior to your last day of employment (collectively, the “ Enhanced Severance Amount ”). The Enhanced Severance Amount will be paid to you in installments over an 18 month period, in accordance with the Company’s normal payroll cycle, with the first installment paid during the first payroll period following the expiration of the release revocation period described below. In addition to the Enhanced Severance Amount, you will be entitled to receive a pro-rata AIP for the year in which your termination occurred, with such pro-rata AIP paid at the same time described above.
     
Release Required to    
Receive Severance:   In order to receive the severance pay and other benefits described above, you must, no later than 60 days following your last day of employment, execute (and not revoke) a general release and waiver of any claims that you may have in connection with your employment and termination of employment with the Company and its affiliates.  Notwithstanding anything in this Agreement to the contrary, if the Company concludes that the severance pay and benefits are subject to Section 409A of the Internal Revenue Code, and if the consideration period described in the release, plus the revocation period described in the release spans two (2) calendar years, then, to the extent required by Section 409A of the Code, such severance payments and benefits shall not begin to be paid until the second calendar year (and such first installment shall include installment payments that would otherwise have been made prior to such date).

 

     

 

 

Jack Phillips

August 6, 2019

Page 7

 

Restrictive Covenants:   This offer is contingent upon you, on your Part-Time Start Date, signing the Restrictive Covenant Agreement attached hereto as Exhibit D .
     
Cooperation:   Following the termination of your service with the Company for any reason, you agree to cooperate fully with the Company and with the Company’s counsel in connection with any present and future actual or threatened litigation, administrative proceeding or other investigation involving the Company or any affiliate that relates to events, occurrences or conduct occurring (or claimed to have occurred) during your employment.  You are hereby instructed to tell the truth in any litigation, administrative proceeding, or other investigation involving the Company and nothing herein shall be deemed or construed to suggest otherwise. If your cooperation is required pursuant to this section, the Company will: (i) reimburse you for reasonable out-of-pocket expenses (excluding legal fees); and (ii) pay you hourly compensation at a rate equivalent to your hourly Base Salary at the time of your termination of employment.
     
Non-Disparagement;    
Social Media:   During the Term and following the termination of your service for any reason, you agree that you will not criticize, defame, be derogatory toward or otherwise disparage the Company, its products, services, or the Company’s past, present and future officers, directors, managers, stockholders, agents, representatives, employees, or affiliates, or its or their business plans or actions, to any third-party, either orally or in writing; provided that that this provision will not preclude you from giving truthful testimony in response to a lawful subpoena or preclude any conduct protected under any local, state or federal law, including those providing “whistleblower” protection to you or the right to engage in concerted activities. The Company also agrees that it will instruct its senior management and Board, as constituted as of your last day of employment, not to  issue any official statements or press releases that disparage you; provided, that, you acknowledge and agree that senior management and the Board are permitted to discuss your employment and performance internally and confidentially as required to conduct business, or to make any legally required disclosures, or if otherwise required under law, in each such instance as reasonably determined by the Company or pursuant to the advice of the Company’s legal counsel. Finally, on the date of your termination of service for any reason, you agree to update your profile on social media websites (such as LinkedIn) to reflect that you are no longer an employee of the Company.
     
Dispute Resolution:   You and the Company agree to meet to informally in a good faith effort to resolve any issues arising under this Agreement . If the parties are unable to resolve their differences, they agree to submit to binding arbitration in Tucson, Arizona, any and all claims and disputes arising hereunder . The parties agree that any dispute will be heard by a single arbitrator, applying Arizona and Federal substantive law, as applicable, in accordance with the American Arbitration Association’s Employment Arbitration Rules . If necessary, an action may be brought in any court of competent jurisdiction solely to compel arbitration or enforce an arbitration award (or for injunctive relief to enforce the Restrictive Covenants of this Agreement) .   This agreement to arbitrate survives the termination of your employment .

 

     

 

 

Jack Phillips

August 6, 2019

Page 8

 

    You expressly agree and understand that, by agreeing to arbitration to resolve all claims described herein, you, as well as the Company, are waiving your right to a jury or court trial for all such claims . You further understand that arbitration is a private, claim resolution process which utilizes a neutral third-party, instead of a judge or jury, to resolve all claims and typically has more limited discovery than in a case filed in court .   You understand that you may refuse to sign this Agreement, but that if the Agreement is not signed, you will not be entitled to the compensation and benefits outlined in this Agreement .
     
      /s/ JP             
    Employee must initial above, indicating his agreement to submit all claims to arbitration.
     
Return of Property:   Upon the Company’s request or your termination of employment for any reason, you shall promptly return to the Company all property of the Company, including but not limited to: originals and hard and electronic copies of records, documents, Confidential Information, computer and office equipment, other equipment, plans, designs, electronic devices, keys, access cards, passwords, credit cards, and other tangible and intangible items, in whatever form, in your possession or control. You understand that all electronic mail, equipment, and all computer hardware and software are property of the Company.
     
Miscellaneous:   To the extent required by law, the Company shall withhold from any payments due to you under this Agreement any applicable federal, state or local taxes. You hereby acknowledge that neither the Company nor any of its affiliates, shareholders, members, directors, managers, officers, employees, agents or representatives have provided you with any tax-related advice with respect to the matters covered by this Agreement and that you are solely responsible for obtaining your own tax advice with respect to the matters covered by this Agreement.
     
    This Agreement shall be governed by and construed in accordance with the laws of the State of Arizona without regard to conflicts of law principles. If any term or provision of this Agreement is declared by a court or tribunal of competent jurisdiction to be invalid or unenforceable for any reason, this Agreement shall remain in full force and effect, and either: (i) the invalid or unenforceable provision shall be modified to the minimum extent necessary to make it valid and enforceable; or (ii) if such a modification is not possible, this Agreement shall be interpreted as if such invalid or unenforceable provision were not a part hereof.

 

     

 

 

Jack Phillips

August 6, 2019

Page 9

 

    Each party acknowledges that such party had the opportunity to be represented by counsel in the negotiation and execution of this Agreement. Accordingly, the rule of construction of contract language against the drafting party is hereby waived by each party.
     
Section 409A of the Code:   This Agreement shall comply with Section 409A of the Internal Revenue Code or an exception thereto and each provision of the Agreement shall be interpreted, to the extent possible, to comply with Section 409A or an exception thereto. Nevertheless, the Company does not and cannot guarantee any particular tax effect or treatment of the amounts due under this Agreement.  Except for the Company’s responsibility to withhold applicable income and employment taxes from compensation paid or provided to you, the Company will not be responsible for the payment of any applicable taxes on compensation paid or provided pursuant to this Agreement. Neither the time nor schedule of any payment under this Agreement may be accelerated or subject to further deferral except as permitted by Section 409A of the Internal Revenue Code and the applicable regulations. You do not have any right to make any election regarding the time or form of any payment due under this Agreement.  Notwithstanding anything in this Agreement to the contrary, if the Company concludes, that the Base Severance Amount or the Enhanced Severance Amount are subject to Section 409A of the Internal Revenue Code, then no such Severance Amount will be paid prior to your “separation from service” as defined in Treasury Regulation Section 1.409A-1(h) (applying the default rules of Treasury Regulation Section 1.409A-1(h)). Installment payments made pursuant to this Agreement shall be treated as separate payments for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii).
     
    If the Base Severance Amount or the Enhanced Severance Amount are subject to Section 409A of the Internal Revenue Code, and if you are a “specified employee” as defined in Treasury Regulation Section 1.409A-1(i)(1) on the date of your termination of employment, such payments shall not begin until the first day of the seventh month following your “separation from service” as defined in Treasury Regulation Section 1.409A-1(h) (applying the default rules of Treasury Regulation Section 1.409A-1(h)) (and such first payment shall include all prior payments that would otherwise have been made prior to such date).

 

     

 

 

Jack Phillips

August 6, 2019

Page 10

 

Section 280G of the Code:   In the event that any payments, distributions, benefits or entitlements of any type payable to you, whether or not payable upon a termination of employment (“ Payments ”): (i) constitute “parachute payments” within the meaning of Section 280G of the Code; and (ii) but for this Section would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code (the “ Excise Tax ”), then the Payments shall be reduced to such lesser amount (the “ Reduced Amount ”) that would result in no portion of the Payments being subject to the Excise Tax; provided , however , that such Payments shall not be so reduced if a nationally recognized accounting firm or compensation consulting firm selected by the Company (the “ Accountants ”) determines that without such reduction, you would be entitled to receive and retain, on a net after-tax basis (including, without limitation, any excise taxes payable under Section 4999 of the Internal Revenue Code, federal, state and local income taxes, social security and Medicare taxes and all other applicable taxes, determined by applying the highest marginal rates which applied (or is likely to apply) to you for the tax year in which the Payments are to be made, or such other rate(s) as the Accountants determine to be likely to apply to you in the relevant tax year(s) in which any of the Payments are expected to be made), an amount that is greater than the amount, on a net after-tax basis, that you would be entitled to retain upon receipt of the Reduced Amount.  Unless otherwise agreed in writing, any determination made under this paragraph shall be made in good faith by the Accountants in a timely manner and shall be binding on the parties absent manifest error. In the event of a reduction of Payments pursuant to this paragraph, the Payments shall be reduced in the order determined by the Accountants that results in the greatest economic benefit to you in a manner that would not result in subjecting you to additional tax under Section 409A of the Internal Revenue Code. For purposes of making the calculations required by this paragraph, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Internal Revenue Code, and other applicable legal authority.  The Accountants shall provide detailed supporting calculations to both you and the Company and the Company shall bear the cost of all fees charged by the Accountants in connection with any calculations contemplated by this paragraph.  If the provisions of Sections 280G and 4999 of the Internal Revenue Code are repealed without succession or if the Company determines that such provisions do not apply to it and/or you for whatever reason, this paragraph shall be of no further force or effect.

 

If you are in agreement with the terms and conditions of this Agreement, please execute and date the Agreement and return a copy to me.

 

  Sincerely,
   
  Accelerate Diagnostics, Inc.
   
  By: /s/ Larry Mehren
  Larry Mehren, President and Chief Executive Officer

 

     

 

 

Jack Phillips

August 6, 2019

Page 11

 

Accepted and agreed to:

 

/s/ John J. Phillips   8/6/19
John J. Phillips   Date

 

     

 

 

Jack Phillips

August 6, 2019

Page 12

 

Exhibit A

 

Part-Time Employee Terms and Conditions

 

Beginning on August 6, 2019, I understand, acknowledge and agree that, in addition to the responsibilities I will have under the Offer Letter attached hereto, I will serve as a part-time employee of Accelerate Diagnostics, Inc. (the “ Company ”) subject to the following:

 

· From August 6, 2019 to September 1, 2019 (the “ Part-Time Employment Period ”), I acknowledge and agree that I will serve as a part-time employee of the Company.

 

· During the Part-Time Employment Period, I acknowledge and agree that my duties and responsibilities will be limited to the following:
o Meeting executive leadership team;
o Meeting sales leadership team;
o Learning microbiology science and industry;
o Reviewing current sales, commercial, and business development plans;
o Participating in strategic planning with the Company’s leadership team; and
o Such additional duties as may be assigned to me by the Company from time to time as long as such additional duties are consistent with my role as a part-time employee.

 

· On my Part-Time Start Date I agree that I will not use or disclose any confidential information that I acquired/will continue to acquire while providing services to Roche Diagnostics Corporation to the Company nor will I use or disclose any confidential information that I acquired/will acquire while providing services to the Company to Roche Diagnostics Corporation.

 

· During the Part-Time Employment Period I acknowledge and agree that I will not have any decision-making authority on behalf of the Company that will conflict in any way to the fiduciary duties I continue to owe to Roche Diagnostics Corporation during the Part-Time Employment Period.

 

Accepted and agreed to:

 

/s/ John J. Phillips   8/6/2019
John J. Phillips   Date

 

Accepted and agreed to solely for the purpose of consenting to the Part-Time Employment Period:

 

/s/ Larry Mehren   8/6/2019
Accelerate Diagnostics, Inc.   Date

 

Accepted and agreed to solely for the purpose of consenting to the Part-Time Employment Period:

 

 /s/ Cindy Carlisle, VP HR   8/1/2019
Roche Diagnostics Corporation   Date

 

     

 

 

Jack Phillips

August 6, 2019

Page 13

 

Exhibit B

 

Offer Letter Definitions

 

Cause ” to terminate your employment shall exist if the Company reasonably determines after due inquiry that any one or more of the following has occurred: (i) your commission or conviction of, or plea of guilty or nolo contendere to, a felony; (ii) your material breach of this Agreement, any other agreement you have entered into with the Company, or of any fiduciary duty you have to the Company; (iii) misconduct that is materially injurious to the Company or a significant violation of the Company’s harassment or discrimination policies; (iv) your habitual drug or alcohol use which materially impairs your ability to perform your duties for the Company; (v) your engaging in fraud, embezzlement or any other illegal conduct that is materially injurious to the Company or any of its affiliates; (vi) deliberate or intentional refusal, or habitual failure to discharge your employment duties, responsibilities or obligations or to follow the Company’s policies or procedures which is not cured, if curable, within 10 days following the Company’s written notice to you of such behavior; or (vii) your engaging in any illegal, unethical, or immoral act (inside or outside of the scope of your employment) that results in material reputational or financial harm to the Company or any of its affiliates. In the case of a termination for Cause as a result of a material breach of this Agreement, you will be provided a written notice describing the breach at least 30 days prior to the proposed termination date and you will have 15 days to cure such breach (and whether such breach is capable of being cured or is adequately cured will be determined by the Company, in good faith). For the avoidance of doubt, the Company will have the right to suspend you with pay during the 30 day notice period and the 15 day cure period described in the preceding sentence.

 

Change of Control ” shall have the meaning ascribed to it in the Equity Plan.

 

Disability ” means you are unable to perform your duties under this Agreement for 90 consecutive days in any 12-month period.

 

Good Reason ” means: (i) a material diminution of your base compensation; (ii) a material diminution of your authorities, duties, or responsibilities; (iii) any action or inaction that constitutes a material breach of this Agreement by the Company; or (iv) material change in the geographic location at which you are required to provide services. For a termination to constitute “Good Reason” for purposes of this Agreement: (1) you must provide a notice of termination to the Company within 30 days of the initial existence of the facts or circumstances constituting such event; (2) the Company must fail to cure such facts or circumstances within 30 days after receipt of such notice; and (3) you must actually terminate your employment within 30 days after the expiration of the cure period described in clause (2).

 

     

 

  

Jack Phillips

August 6, 2019

Page 14

 

Exhibit C

 

Form of Nonqualified Stock Option Agreement

 

     

 

  

Jack Phillips

August 6, 2019

Page 15

 

Exhibit D

 

Employee Restrictive Covenant Agreement

 

In consideration for Accelerate Diagnostics, Inc. (the “ Company ”) agreement to employ me and provide me with the compensation and benefits described in the attached Offer Letter and access to the Company’s Confidential Information (as defined below) and trade secrets, I understand, acknowledge and agree, beginning as of the Part-Time Start Date (as defined in the attached Offer Letter), as follows:

 

Restrictive Covenants:   Non-Solicitation of Customers/Prospective Customers . You agree, for the duration of the Time Limit (as defined below), that you will not, either directly or indirectly, or in any individual or representative capacity, request or solicit any of the Company’s current customers or clients with whom you have had contact in the past year to withdraw, curtail, cancel, or decrease the level of their business with the Company or request that they do business with any third party in competition with the Company. You further agree that, for the duration of the Time Limit, you will not, either directly or indirectly, or in any individual or representative capacity, request or solicit any of the Company’s prospective customers (defined as any person or entity who has been directly solicited to become a customer or client by the Company and with whom you have had contact with within the past year or possesses Confidential Information about) or clients with whom you have had contact with in the past year or possesses Confidential Information about to forgo doing business with the Company or request that such prospective customer or client do business with any third party in competition with the Company.
     
    Non-Solicitation of Employees/Applicants .  You agree, for the duration of the Time Limit, that you will not, either directly or indirectly, or in any individual or representative capacity, solicit, induce or encourage or attempt to solicit, induce or encourage any Company employee and/or applicant to terminate his/her employment or prospective employment with the Company.
     
    Non-Competition .  You agree, for the duration of the Time Limit, (as defined below), that you will not, either directly or indirectly or in any individual or representative capacity, be employed by, engage, own, manage, operate, control, aid, or assist another in the operation, organization or promotion of, participate in, advise, contract with or otherwise engage in any manner with the ownership, management, operation, or control of any business, which has a place of business or regularly conducts business in the Geographical Limit (as defined below) and that promotes or sells products or services competitive with those of the Company. You acknowledge and agree that a business will be deemed “competitive” with the Company if it performs any of the services or produces, distributes or sells any of the products or services provided or offered by the Company during the term of your relationship with the Company.

 

     

 

  

Jack Phillips

August 6, 2019

Page 16

 

    Tolling .    The non-competition and non-solicitation Time Limits set forth above shall be tolled during any period in which you are in breach of the restrictions set forth herein.
     
    Reasonable Limitations .  You hereby acknowledge and agree that the covenants and obligations made and undertaken in this Agreement are fair and reasonable with respect to duration, geographic area and scope of activity, and do not (and shall not) prevent you from earning a livelihood in complying with the covenants herein.
     
    Injunctive Relief. You agree that a breach of the covenants described herein will result in substantial and irreparable damages to the Company, which would be difficult to fully ascertain and calculate, and, by reason of such fact, you agree that, in the event of any such breach or threatened or anticipated breach, the Company will have the right to a restraining order and injunction, both temporary and permanent, enjoining and restraining any such breach or threatened breach, without the necessity of proving actual damages or posting a bond. Such injunctive relief will be in addition to any other remedies available to the Company at law or in equity.
     
    Survival of Restrictive Covenants .  Your acknowledgements and agreements set forth in this Agreement shall survive the expiration or termination of this Agreement and the termination of your employment with the Company for any reason.
     
Notice to Future Employers:   You agree that you will notify, and the Company shall have the right to notify, any future or prospective employers, or individuals or entities with whom you may be entering into a contractual relationship, of the Restrictive Covenant provisions of this Agreement for purposes of ensuring that the Company’s interests are protected.
     
Company Proprietary    
Information:   While you are providing services to the Company, the Company may disclose or make available to you, Confidential Information.  By signing this Agreement, you agree to: (i) protect and safeguard the confidentiality of the Confidential Information with at least the same degree of care as you would protect your own confidential information, but in no event with less than a commercially reasonable degree of care; and (ii) not use or disclose the Confidential Information, or permit it to be accessed, used or disclosed, for any purpose other than to carry out the duties assigned to you by the Company or as may be required to be disclosed pursuant to applicable federal, state or local law, regulation or a valid order issued by a court or governmental agency of competent jurisdiction. Upon your termination of service for any reason, or upon the Company’s written request, you shall promptly return to the Company all copies, whether in written, electronic or other form or media, of the Confidential Information, or destroy all such copies at the Company’s written request and certify in writing to the Company that such Confidential Information has been destroyed. In addition to all other remedies available at law, the Company may seek equitable relief (including injunctive relief) against you to prevent the breach or threatened breach of this confidentiality covenant and to secure its enforcement. Notwithstanding anything in this Agreement to the contrary, pursuant to the Defend Trade Secrets Act of 2016, you shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  If you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the Company’s trade secrets to your attorney and use the trade secret in the court proceeding, if you file any document containing the trade secret under seal and do not disclose the trade secret, except pursuant to court order.

 

     

 

 

Jack Phillips

August 6, 2019

Page 17

 

    In addition to the obligations above, we may ask that you also sign the Company’s standard Confidentiality and Intellectual Property Assignment Agreement.  
     
Definitions:   For purposes of this Agreement, the following terms shall have the following meanings:
     
    Confidential Information means non-public information about the Company’s business affairs, products, services, confidential intellectual property, trade secrets, third-party confidential information and other sensitive or proprietary information, whether orally or in written, electronic or other form or media, and whether or not marked, designated or otherwise identified as “confidential.” Confidential Information shall not include information that, at the time of disclosure and as established by documentary evidence: (i) is or becomes generally available to and known by the public other than as a result of, directly or indirectly, any breach of this Agreement by you; (ii) is or becomes available to you on a non-confidential basis from a third-party source, provided that such third-party is not and was not prohibited from disclosing such Confidential Information; (iii) was known by or in the possession of you prior to being disclosed by or on behalf of the Company; or (iv) was or is independently developed by you without reference to or use, in whole or in part, of any of the Confidential Information.
     
    Geographical Limit means the United States of America; if a court determines that the United States of America is too broad, then the state of Arizona; if a court determines that Arizona is too broad, then Maricopa and Pima County; if a court determines that Maricopa and Pima County is too broad, then Pima County only; if a court determines that Pima County is too broad, then Tucson, Arizona.
     
    Time Limit means the term of your employment with the Company and for a period of 18 months thereafter; if a court determines that 18 months is longer than necessary to protect the Company’s legitimate interests, then 12 months; if a court determines 12 months is longer than necessary to protect the Company’s legitimate interests, then 9 months.

 

     

 

  

Jack Phillips

August 6, 2019

Page 18

 

Miscellaneous:   This Agreement shall be governed by and construed in accordance with the laws of the State of Arizona without regard to conflicts of law principles. If any term or provision of this Agreement is declared by a court or tribunal of competent jurisdiction to be invalid or unenforceable for any reason, this Agreement shall remain in full force and effect, and either: (i) the invalid or unenforceable provision shall be modified to the minimum extent necessary to make it valid and enforceable; or (ii) if such a modification is not possible, this Agreement shall be interpreted as if such invalid or unenforceable provision were not a part hereof.
     
    Each party acknowledges that such party had the opportunity to be represented by counsel in the negotiation and execution of this Agreement. Accordingly, the rule of construction of contract language against the drafting party is hereby waived by each party.
     
    The dispute resolution provisions of the Offer Letter attached hereto are incorporated by reference and by signing below you acknowledge and agree that any dispute arising under this Agreement will be resolved in accordance with the procedures set forth in the Offer Letter.

 

Accepted and agreed to:

 

/s/ John J. Phillips   8/6/2019
John J. Phillips   Date

 

     

 

EXHIBIT 10.2

 

ACCELERATE DIAGNOSTICS, INC.

2012 OMNIBUS EQUITY INCENTIVE PLAN

NOTICE OF GRANT OF NONQUALIFIED STOCK OPTIONS

 

This Nonqualified Stock Option Agreement consists of this Notice of Grant of Nonqualified Stock Options (the “ Grant Notice ”) and the Nonqualified Stock Option Award Agreement immediately following. The Nonqualified Stock Option Agreement sets forth the specific terms and conditions governing Nonqualified Stock Option Awards under the Accelerate Diagnostics, Inc. 2012 Omnibus Equity Incentive Plan (the “ Plan ”). All of the terms of the Plan are incorporated herein by reference.

 

Name of Optionee:   Jack Phillips
     
Total No. of shares of Stock subject to the Option:   1,249,917
     
Date of Grant:   August 6, 2019
     
Expiration Date:   August 6, 2029
     
Exercise Price:   $17.00
     
Vesting Schedule:   Subject to Grantee’s continued employment: forty percent (40%) of the shares of Stock subject to the Option shall vest and become exercisable on the second anniversary of the Date of Grant. The remaining sixty percent (60%) of the shares of Stock subject to the Option shall vest and become exercisable in equal monthly installments, on the same numbered day, over the next thirty-six (36) months thereafter with the first installment vesting on the last day of the first month following the second anniversary of the Date of Grant.

 

by ACCEPTING this NONQUALIFIED stock option AGREEMENT (WHETHER THROUGH ELECTRONIC SIGNATURE OR OTHER MEANS), optionee accepts participation in the plan, acknowledges that he or she has read and understands the provisions of this grant NOTICE and the plan, and agrees that this grant NOTICE, the award agreement AND THE pLAN shall govern the terms and conditions of thIS AWARD.

 

IN WITNESS WHEREOF , the Company has duly executed this Nonqualified Stock Option Agreement, and this Nonqualified Stock Option Agreement shall be effective as of the Date of Grant set forth above.

 

  ACCELERATE DIAGNOSTICS, INC.
   
  By: /s/ Steven Reichling
   
  Print Name: Steven Reichling
   
  Its:  Chief Financial Officer

 

     

 

 

NONQUALIFIED STOCK OPTION AWARD AGREEMENT

UNDER THE ACCELERATE DIAGNOSTICS, INC.

2012 OMNIBUS EQUITY INCENTIVE PLAN

 

This Nonqualified Stock Option Award Agreement (this “ Agreement ”) is between Accelerate Diagnostics, Inc. (f/k/a Accelr8 Technology Corporation), a Delaware corporation (the “ Company ”) and the individual (the “ Optionee ”) identified in the Notice of Grant of Nonqualified Stock Options (the “ Grant Notice ”), and is effective as of the date of grant referenced in the Grant Notice (the “ Date of Grant ”). This Agreement supplements the Grant Notice to which it is attached, and, together, with the Grant Notice, constitutes the “Nonqualified Stock Option Agreement” referenced in the Grant Notice.

 

RECITALS

 

A.            The Board of Directors of the Company (the “ Board ”) has adopted and the shareholders have approved the Accelerate Diagnostics, Inc. 2012 Omnibus Equity Incentive Plan (the “ Plan ”) to promote the success an enhance the value of the Company by linking the personal interests of the Plan’s participants to those of the Company’s shareholders by providing such individuals with an incentive for outstanding performance.

 

B.            The Compensation Committee of the Board (or its designee) has approved this grant of Nonqualified Stock Options to Optionee pursuant to Section 7.1 of the Plan.

 

C.            To the extent not specifically defined in this Agreement, all capitalized terms used in this Agreement shall have the meaning set forth in the Plan.

 

D.            In consideration of the mutual covenants and conditions hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Optionee agree as follows:

 

AGREEMENT

 

1.            Grant of Option . Subject to the terms of this Agreement and Section 7.1 of the Plan, the Company grants to Optionee the right and option to purchase from the Company all or any part of the aggregate number of shares of Stock specified in the Grant Notice (“ Option ”). The Option granted under this Agreement is not intended to be an “Incentive Stock Option” under Section 422 of the Internal Revenue Code of 1986, as amended (the “ Code ”).

 

2.            Exercise Price . The exercise price under this Agreement is the exercise price per share of Stock specified in the Grant Notice, as determined by the Committee, which shall not be less than the Fair Market Value of a share of Stock on the Date of Grant.

 

3.            Vesting of Option . The Option shall vest and become exercisable according to the vesting schedule set forth in the Grant Notice, provided, that all of the shares of Stock subject to the Option shall fully vest upon the closing of a transaction that result in a Change of Control.

 

4.            Exercise of Option . This Option may be exercised in whole or in part at any time after it vests in accordance with Section 3 and before the Option expires by delivery of a written notice of exercise (under Section 5 below) and payment of the exercise price. The exercise price may be paid in cash, or shares of Stock held for longer than six months (through actual tender or by attestation), or such other method permitted by the Committee (including broker-assisted “cashless exercise” arrangements) and communicated to the Optionee before the date the Optionee exercises the Option.

 

     

 

  

5.            Method of Exercising Option . Subject to the terms of this Agreement, the Option may be exercised by timely delivery to the Company of written (or electronic) notice, which notice shall be effective on the date received by the Company. The notice shall state the Optionee’s election to exercise the Option and the number of underlying shares in respect of which an election to exercise has been made. Such notice shall be signed (including by electronic signature) by the Optionee, or if the Option is exercised by a person or persons other than the Optionee because of the Optionee’s death, such notice must be signed (including by electronic signature) by such other person or persons and shall be accompanied by proof acceptable to the Committee of the legal right of such person or persons to exercise the Option.

 

6.            Term of Option . The Option granted under this Agreement expires, unless sooner terminated, ten (10) years from the Date of Grant, through and including the normal close of business of the Company on the tenth (10 th ) anniversary of the Date of Grant (the “ Expiration Date ”).

 

7.            Termination of Employment (or Service) .

 

(a)           If the Optionee terminates employment (or service) for any reason other than death or Disability, the Option shall lapse on the earlier of: (i) the Expiration Date; or (ii) ninety (90) days after the date the Optionee terminates employment (or service). The Option may be exercised following the Optionee’s termination of employment (or service) only if the Option was exercisable by Optionee immediately prior to his or her termination of employment (or service). In no event shall the Option be exercisable after the Expiration Date.

 

(b)           If the Optionee terminates employment (or service) by reason of death or Disability, the Option shall lapse on the earlier of: (i) the Expiration Date; or (ii) twelve (12) months after the date the Optionee terminates employment (or service) due to death or Disability. The Option may be exercised following the death or Disability of Optionee only if the Option was exercisable by Optionee immediately prior to his or her death or Disability. In no event shall the Option be exercisable after the Expiration Date.

 

8.            Withholding . As described in Section 16.3 of the Plan, the Company shall have the right to deduct or withhold, or to require the Optionee to remit to the Company, the minimum amount necessary to satisfy any federal, state or local taxes (including the Optionee’s FICA obligation) as are required by law to be withheld with respect to the Options granted pursuant this Agreement.

 

9.            Nontransferability of Options . The Options granted by this Agreement shall not be transferable by the Optionee or any other person claiming through the Optionee, either voluntarily or involuntarily, except by will or the laws of descent and distribution or as otherwise provided by the Committee pursuant to Section 7.1(f) and Article 13 of the Plan.

 

10.          No Right to Continued Employment (or Service) . This Agreement shall not be construed to confer upon the Optionee any right to continue employment (or service) with the Company and shall not limit the right of the Company, in its sole and absolute discretion, to terminate Optionee’s employment (or service) at any time.

 

11.          Administration . This Agreement shall at all times be subject to the terms and conditions of the Plan and the Plan shall in all respects be administered by the Committee in accordance with the terms of and as provided in the Plan. The Committee shall have the sole and complete discretion with respect to all matters reserved to it by the Plan and decisions of the Committee with respect thereto and to this Agreement shall be final and binding upon the Optionee and the Company. In the event of any conflict between the terms and conditions of this Agreement and the Plan, the provisions of the Plan shall control.

 

     

 

  

12.          Adjustments . The number of shares of Stock issued to Optionee pursuant to this Agreement shall be adjusted by the Committee pursuant to Section 4.4 of the Plan, in its discretion, in the event of a change in the Company’s capital structure.

 

13.          Securities Laws Compliance . The Company shall not be required to deliver any shares of Stock pursuant to the exercise of the Option if, in the opinion of counsel for the Company, such issuance would violate the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other applicable federal or state securities laws or regulations.

 

14.          No Shareholders Rights . The Optionee will have no voting rights or any other rights as a shareholder of the Company with respect to the Option until the Company issues the stock certificates representing the shares of Stock underlying the Option.

 

15.          Copy of Plan . By accepting this Agreement (whether through electronic signature or other means), the Optionee acknowledges receipt of a copy of the Plan.

 

16.          Governing Law . This Agreement shall be interpreted and administered under the laws of the State of Delaware.

 

17.          Amendment . Except as otherwise provided in the Plan, this Agreement may be amended only by a written agreement executed by the Company and the Optionee. The provisions of this Agreement may not be waived or modified unless such waiver or modification is in writing and signed by a representative of the Committee.

 

18.          Clawback . Pursuant to Section 13.4 of the Plan, every Award issued pursuant to the Plan is subject to potential forfeiture or “clawback” to the fullest extent called for by applicable federal or state law or any policy of the Company. By accepting this Award (whether through electronic signature or other means), Optionee agrees to be bound by, and comply with, the terms of any such forfeiture or “clawback” provision imposed by applicable federal or state law or prescribed by any policy of the Company.

 

19.          Electronic Signature . The Optionee acknowledges that Optionee’s electronic signature has the same legal force and effect as a written or manual signature.

 

MANY OF THE PROVISION OF THIS AWARD AGREEMENT ARE SUMMARIES OF SIMILAR PERTINENT PROVISIONS OF THE PLAN. TO THE EXTENT THAT THIS AGREEMENT IS SILENT ON AN ISSUE OR THERE IS A CONFLICT BETWEEN THE PLAN AND THIS AGREEMENT, THE PLAN PROVISIONS SHALL CONTROL.

 

     

 

EXHIBIT 99.1

 

Accelerate Diagnostics Reports Second Quarter 2019 Financial Results

 

TUCSON, Ariz., August 8, 2019 -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2019.

 

“We achieved mixed results in the second quarter, as revenue and placements were both lighter than anticipated due to lower-than-expected capital sales in our EMEA region,” commented Lawrence Mehren, president and CEO of Accelerate Diagnostics, Inc. “However, we were encouraged by our commercial progress during the quarter, highlighted by 30% sequential growth in consumable sales and by our signing of the Mayo Clinic as a key reference customer. We expect our increasingly strong customer pipeline to drive higher placements in the second half of the year, particularly in Q4, and are confident that consumable revenues will continue to ramp higher as an ever-increasing number of new customers go clinically live.”

 

Second Quarter 2019 Highlights

 

· Added 55 net new commercially contracted instruments, compared to 29 in the second quarter of 2018.

 

· Net sales of $1.8 million, compared to $1.7 million in the second quarter of 2018. Instrument revenue decreased year-over-year while consumable revenue grew meaningfully over the same time period, reflecting the company’s change to a reagent rental business model starting Q3 of 2018. Consumable revenue grew by over 125% as compared the second quarter of 2018 and by approximately 30% over the prior quarter.

 

· Gross margin was 50% for the quarter, compared to 58% in the second quarter of 2018 . This decrease was the result of one-time inventory timing benefits in the prior year which did not repeat in the current year.

 

· Selling, general, and administrative expenses for the quarter were $12.8 million, compared to $15.3 million in the second quarter of 2018. This decrease was driven by lower stock-based compensation expense in the current year.

 

· Research and development (R&D) costs for the quarter were $6.1 million, compared to $6.1 million in the second quarter of 2018. R&D expense were materially unchanged due to a stable product development program.

 

· Net loss was $20.8 million in the second quarter, or $0.38 per share, which included $2.9 million in non-cash stock-based compensation expense.

 

· Net cash used in the quarter was $13.0 million, and the company ended the quarter with total cash, investments, and cash equivalents of $137.8 million.

 

Year to Date 2019 Highlights

 

· Added 130 net new commercially contracted instruments year to date, compared to 40 for the same period from 2018.

 

· Net sales of $3.6 million year to date, compared to $2.5 million for the same period from 2018. Instrument revenue decreased while consumable revenue grew steadily reflecting the company’s change to a reagent rental business model starting Q3 of 2018. Consumable revenue grew by over 125% year to date compared to the same period in the prior year.

 

· Gross margin was 49% year to date, compared to 51% for the same period from 2018. This decrease was in part due to one-time inventory timing benefits in the prior year that did repeat in the current year. After excluding the impacts of pre-FDA inventory previously written off to R&D, gross margin improved by 300 basis points year to date to due to higher test kit production levels.

 

· Selling, general, and administrative expenses were $25.6 million year to date, compared to $29.7 million for the same period from 2018. This decrease was driven by lower stock-based compensation expense in the current year.

 

· Research and development (R&D) costs were $13.1 million year to date, compared to $12.8 million for the same period from 2018. R&D expense remain unchanged due to a stable product development program.

 

· Net loss was $42.5 million year to date, or $0.78 per share, which included $6.3 million in non-cash stock-based compensation expense.

 

· Net cash used year to date was $28.6 million, and the company ended the quarter with total cash, investments, and cash equivalents of $137.8 million.

 

Full financial results for the quarter ending June 30, 2019 will be filed on Form 10-Q through the Securities and Exchange Commission’s (SEC) website at http://www.sec.gov .

 

Audio Webcast and Conference Call

 

The company will host a conference call at 4:30PM ET today to review its second quarter results. To participate in the conference call, dial +1.877.883.0383 and enter the conference ID: 8768870. International participants may dial +1.412.902.6506. Please dial in 10 to 15 minutes prior to the start of the conference call. A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (international) using replay code 10132228 until August 29, 2019.

 

  1  

 

 

This conference call will also be webcast and can be accessed from the “Investors” section of the company’s website at axdx.com/investors . A replay of the audio webcast will be available until August 29, 2019.

 

About Accelerate Diagnostics, Inc.

 

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.

 

The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

 

For more information about the company, its products and technology, or recent publications, visit axdx.com .

 

Forward-Looking Statements

 

Certain of the statements made in this press release are forward looking, such as those, among others, about the company’s projections as to when certain key business milestones may be achieved, the potential of the company’s products or technology, the growth of the market, the company’s estimates as to the size of its market opportunity and potential pricing, the company’s competitive position and estimates of time reduction to results, and its future development plans and growth strategy. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 1, 2019, and in any other reports that the company files with the Securities and Exchange Commission. The company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.

 

###

 

Investor Inquiries:

Laura Pierson, Accelerate Diagnostics, +1 520 365-3100, investors@axdx.com

 

Media Contact:

Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100, achasteen@axdx.com

 

Source: Accelerate Diagnostics Inc.

 

  2  

 

 

ACCELERATE DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED

BALANCE SHEET

(in thousands, except share data)

 

    June 30,     December 31,  
    2019     2018  
    Unaudited        
ASSETS                
Current assets:                
Cash and cash equivalents   $ 87,469     $ 66,260  
Investments     50,349       100,218  
Trade accounts receivable     1,911       1,860  
Inventory     8,298       7,746  
Prepaid expenses     1,342       980  
Other current assets     805       576  
Total current assets     150,174       177,640  
Property and equipment, net     7,624       7,303  
Right of use assets     375        
Other non-current assets     471       322  
Total assets   $ 158,644     $ 185,265  
LIABILITIES AND STOCKHOLDERS’ EQUITY                
Current liabilities:                
Accounts payable   $ 1,819     $ 1,322  
Accrued liabilities     3,976       4,962  
Accrued interest     1,262       1,262  
Deferred revenue and income     255       217  
Current operating lease liability     200        
Total current liabilities     7,512       7,763  
Non-current operating lease liability     175        
Other non-current liabilities     35       53  
Convertible notes     124,917       120,074  
Total liabilities   $ 132,639     $ 127,890  
Commitments and contingencies                
                 
Stockholders’ equity:                
Preferred shares, $0.001 par value;                
5,000,000 preferred shares authorized and none outstanding as of June 30, 2019 and December 31, 2018            
Common stock, $0.001 par value;                
85,000,000 common shares authorized with 54,512,492 shares issued and outstanding on June 30, 2019 and 75,000,000 common shares authorized with 54,231,876 shares issued and outstanding on December 31, 2018     55       54  
Contributed capital     443,857       432,885  
Treasury stock     (45,067 )     (45,067 )
Accumulated deficit     (372,884 )     (330,348 )
Accumulated other comprehensive income (loss)     44       (149 )
Total stockholders’ equity     26,005       57,375  
Total liabilities and stockholders’ equity   $ 158,644     $ 185,265  

  

See accompanying notes to condensed consolidated financial statements.

 

  3  

 

 

ACCELERATE DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Unaudited

(in thousands, except per share data)

 

    Three Months Ended     Six Months Ended  
    June 30,     June 30,     June 30,     June 30,  
    2019     2018     2019     2018  
Net sales   $ 1,806     $ 1,692     $ 3,557     $ 2,493  
                                 
Cost of sales     907       717       1,823       1,210  
Gross profit     899       975       1,734       1,283  
                                 
Costs and expenses:                                
Research and development     6,149       6,060       13,083       12,842  
Sales, general and administrative     12,837       15,330       25,559       29,682  
Total costs and expenses     18,986       21,390       38,642       42,524  
                                 
Loss from operations     (18,087 )     (20,415 )     (36,908 )     (41,241 )
                                 
Other income (expense):                                
Interest expense     (3,528 )     (3,205 )     (6,987 )     (3,363 )
Foreign currency exchange (loss) gain     6       (253 )     (53 )     (198 )
Interest income     812       774       1,653       1,075  
Other expense, net     (1 )     (25 )     (3 )     (25 )
Total other expense, net     (2,711 )     (2,709 )     (5,390 )     (2,511 )
                                 
Net loss before income taxes     (20,798 )     (23,124 )     (42,298 )     (43,752 )
Provision for income taxes     (17 )     (101 )     (238 )     (285 )
Net loss   $ (20,815 )   $ (23,225 )   $ (42,536 )   $ (44,037 )
                                 
Basic and diluted net loss per share   $ (0.38 )   $ (0.43 )   $ (0.78 )   $ (0.80 )
Weighted average shares outstanding     54,476       54,003       54,407       54,821  
                                 
Other comprehensive loss:                                
Net loss   $ (20,815 )   $ (23,225 )   $ (42,536 )   $ (44,037 )
Net unrealized gain (loss) on available-for-sale investments     98       (2 )     219       (55 )
Foreign currency translation adjustment     50       (191 )     (26 )     (79 )
Comprehensive loss   $ (20,667 )   $ (23,418 )   $ (42,343 )   $ (44,171 )

 

See accompanying notes to condensed consolidated financial statements.

 

  4  

 

 

ACCELERATE DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF CASH FLOWS

Unaudited

(in thousands)

 

    Six Months Ended  
    June 30,     June 30,  
    2019     2018  
Cash flows from operating activities:                
Net loss   $ (42,536 )   $ (44,037 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization     1,236       1,082  
Amortization of investment discount     (320 )     (146 )
Equity-based compensation     6,278       9,011  
Amortization of debt discount and issuance costs     4,843       2,273  
Loss on disposal of property and equipment     407       266  
(Increase) decrease in assets:                
Accounts receivable     (51 )     123  
Inventory     (2,217 )     (4,334 )
Prepaid expense and other     (588 )     (697 )
Increase (decrease) in liabilities:                
Accounts payable     476       206  
Accrued liabilities, and other     (1,110 )     661  
Accrued interest           1,105  
Deferred revenue and income     38       (935 )
Deferred compensation     (18 )     5  
Net cash used in operating activities     (33,562 )     (35,417 )
Cash flows from investing activities:                
Purchases of equipment     (76 )     (702 )
Purchase of marketable securities     (17,601 )     (91,272 )
Proceeds from sales of marketable securities     13,400       3,000  
Maturities of marketable securities     54,447       38,272  
Net cash provided by (used in) investing activities     50,170       (50,702 )
Cash flows from financing activities:                
Proceeds from issuance of common stock     251       276  
Proceeds from exercise of options     4,369       2,757  
Proceeds from issuance of convertible note           171,499  
Prepayment of forward stock repurchase transaction           (45,069 )
Payment of debt issuance costs           (4,991 )
Net cash provided by financing activities     4,620       124,472  
                 
Effect of exchange rate on cash     (19 )     (56 )
                 
Increase in cash and cash equivalents     21,209       38,297  
Cash and cash equivalents, beginning of period     66,260       28,513  
Cash and cash equivalents, end of period   $ 87,469     $ 66,810  

  

See accompanying notes to condensed consolidated financial statements.

 

  5  

 

 

EXHIBIT 99.2

 

 

Accelerate Diagnostics Names Jack Phillips Chief Operating Officer

 

TUCSON, Ariz., August 8, 2019 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that Jack Phillips has been appointed Chief Operating Officer. Mr. Phillips joins Accelerate from Roche Diagnostics, the world’s leading diagnostics company.

 

Lawrence Mehren, President and Chief Executive Officer of Accelerate Diagnostics, commented, “We are thrilled to have an accomplished commercial leader of Jack’s caliber join our team. This is an exciting time for Accelerate as we approach an inflection point in our commercial growth. Jack’s experience and operational acumen are second to none, and we believe his leadership will enable us to more effectively leverage our momentum and take our growth to the next level.”

 

“I am very excited to join the talented team at Accelerate Diagnostics. The Accelerate Pheno technology addresses a significant unmet medical need in antibiotic resistance and hospital-acquired infections, and I am thrilled with the opportunity to help advance this critically important mission. I look forward to working closely with the team to deliver sustainable top- and bottom-line improvements while making this life-saving technology accessible to as many patients as possible,” said Mr. Phillips.

 

Mr. Phillips has an exceptional track record in laboratory diagnostics. Under his leadership since 2010, Roche Diagnostics moved from third in market share to become the top-ranked in vitro diagnostics (IVD) company in North America. In successive leadership roles spanning nearly a decade, Mr. Phillips also played an instrumental role in the growth of Ventana Medical Systems prior to its acquisition by Roche in 2008. During his tenure as Senior Vice President and General Manager of North America, Ventana’s revenue grew from $69 million to $375 million, and its market share grew from around 20% to 64%.

 

About Accelerate Diagnostics, Inc.

 

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The FDA-cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours, direct from positive blood cultures. Recent external studies indicate the solution offers results 1–2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage—specific to the individual patient's infection—days earlier.

 

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

 

For more information about the company, its products and technology, or recent publications, visit axdx.com .

 

Forward-Looking Statements

 

Certain of the statements made in this press release are forward looking, such as those, among others, about the company’s projections as to when certain key business milestones may be achieved, the potential of the company’s products or technology, the growth of the market, the company’s estimates as to the size of its market opportunity and potential pricing, the company’s competitive position and estimates of time reduction to results, and its future development plans and growth strategy. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned “Risk Factors” in the company’s most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission. The company’s forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.

 

###

 

Investor Inquiries:

Laura Pierson, Accelerate Diagnostics, +1 520 365-3100, investors@axdx.com

 

Media Contact:

Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100, achasteen@axdx.com

 

Source: Accelerate Diagnostics, Inc.